Bruker Cellular Analysis (CELL) 10-Q 15 May 23 2023 Q1 Quarterly report Financial data

Cover

Cover - shares	3 Months Ended
	Mar. 31, 2023	Apr. 30, 2023
Cover [Abstract]
Document Type	10-Q
Document Quarterly Report	true
Document Period End Date	Mar. 31, 2023
Document Transition Report	false
Entity File Number	001-39388
Entity Registrant Name	PhenomeX Inc.
Entity Incorporation, State or Country Code	DE
Entity Tax Identification Number	35-2415390
Entity Address, Address Line One	5858 Horton Street, Suite 320
Entity Address, City or Town	Emeryville
Entity Address, State or Province	CA
Entity Address, Postal Zip Code	94608
City Area Code	510
Local Phone Number	858-2855
Title of 12(b) Security	Common stock, $0.00005 par value
Trading Symbol	CELL
Security Exchange Name	NASDAQ
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Non-accelerated Filer
Entity Small Business	true
Entity Emerging Growth Company	false
Entity Shell Company	false
Entity Common Stock, Shares Outstanding		98,795,621
Entity Central Index Key	0001689657
Current Fiscal Year End Date	--12-31
Document Fiscal Year Focus	2023
Document Fiscal Period Focus	Q1
Amendment Flag	false

Condensed Consolidated Balance

Condensed Consolidated Balance Sheets (Unaudited) - USD ($) $ in Thousands	Mar. 31, 2023	Dec. 31, 2022
Current assets:
Cash and cash equivalents	$ 51,606	$ 86,522
Short-term marketable securities	0	46,252
Trade accounts receivable, net	25,119	18,534
Inventory	45,539	18,861
Prepaid expenses and other current assets	9,378	6,783
Total current assets	131,642	176,952
Restricted cash	70,093	0
Property and equipment, net	33,842	23,847
Operating lease right-of-use assets	27,449	23,326
Goodwill	12,246	0
Intangible assets, net	23,072	0
Other assets	2,217	1,969
Total assets	300,561	226,094
Current liabilities:
Trade accounts payable	17,051	10,092
Accrued expenses and other current liabilities	19,645	21,340
Current portion of long-term debt	0	4,966
Deferred revenue	10,746	9,092
Total current liabilities	47,442	45,490
Long-term debt	68,886	14,860
Deferred revenue, net of current portion	1,259	963
Lease liability, long-term	25,234	22,726
Total liabilities	142,821	84,039
Commitments and contingencies (Note 17)
Stockholders’ equity:
Common stock, $0.00005 par value. Authorized 300,000,000 shares at March 31, 2023 and December 31, 2022; issued and outstanding 98,744,915 and 72,169,052 shares at March 31, 2023 and December 31, 2022, respectively	5	4
Additional paid-in capital	542,805	503,708
Accumulated deficit	(385,067)	(361,648)
Accumulated other comprehensive loss	(3)	(9)
Total stockholders’ equity	157,740	142,055
Total liabilities and stockholders’ equity	$ 300,561	$ 226,094

Condensed Consolidated Balanc_2

Condensed Consolidated Balance Sheets (Unaudited) (Parenthetical) - $ / shares	Mar. 31, 2023	Dec. 31, 2022
Statement of Financial Position [Abstract]
Common stock, par value (in dollars per share)	$ 0.00005	$ 0.00005
Common stock authorized (in shares)	300,000,000	300,000,000
Common stock issued (in shares)	98,744,915	72,169,052
Common stock outstanding (in shares)	98,744,915	72,169,052

Condensed Consolidated Statemen

Condensed Consolidated Statements of Operations (Unaudited) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2023	Mar. 31, 2022
Revenue:
Total revenue	$ 18,516	$ 20,206
Cost of sales:
Total cost of sales	5,088	6,379
Gross profit	13,428	13,827
Operating expenses:
Research and development	8,421	17,573
Selling, general and administrative	26,547	17,527
Restructuring	1,290	0
Total operating expenses	36,258	35,100
Loss from operations	(22,830)	(21,273)
Other income (expense):
Interest expense	(384)	(224)
Interest income	827	34
Other income (expense), net	(1,012)	57
Loss before income taxes	(23,399)	(21,406)
Provision for income taxes	20	20
Net loss	$ (23,419)	$ (21,426)
Net loss attributable to common stockholders per share, basic (in dollars per share)	$ (0.31)	$ (0.32)
Net loss attributable to common stockholders per share, diluted (in dollars per share)	$ (0.31)	$ (0.32)
Weighted-average shares used in calculating net loss per share, basic (in shares)	75,759,771	67,697,488
Weighted-average shares used in calculating net loss per share, diluted (in shares)	75,759,771	67,697,488
Product
Revenue:
Total revenue	$ 8,378	$ 9,774
Cost of sales:
Total cost of sales	3,912	2,695
Service and other revenue
Revenue:
Total revenue	10,138	10,432
Cost of sales:
Total cost of sales	$ 1,176	$ 3,684

Condensed Consolidated Statem_2

Condensed Consolidated Statements of Comprehensive Loss (Unaudited) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2023	Mar. 31, 2022
Statement of Comprehensive Income [Abstract]
Net loss	$ (23,419)	$ (21,426)
Other comprehensive loss:
Foreign currency translation adjustments	(3)	0
Unrealized gain on marketable securities, net of tax	9	0
Other comprehensive income:	6	0
Comprehensive loss	$ (23,413)	$ (21,426)

Condensed Consolidated Statem_3

Condensed Consolidated Statements of Changes in Stockholders' Equity (Unaudited) - USD ($) $ in Thousands		Total	Common Stock	Additional Paid-in Capital	Accumulated Deficit	Accumulated Other Comprehensive Loss
Beginning balance (in shares) at Dec. 31, 2021			67,595,535
Beginning balance at Dec. 31, 2021		$ 208,216	$ 4	$ 471,820	$ (263,608)	$ 0
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Exercise of stock options (in shares)			81,654
Exercise of stock options		412		412
Vesting of restricted stock units (in shares)			27,580
Employee stock purchase plan (in shares)			115,346
Employee stock purchase plan		610		610
RSUs issued for 2022 Bonuses		0
Stock-based compensation		5,389		5,389
Foreign currency translation adjustments		0
Net loss		(21,426)			(21,426)
Ending balance (in shares) at Mar. 31, 2022			67,820,115
Ending balance at Mar. 31, 2022		193,201	$ 4	478,231	(285,034)	0
Beginning balance (in shares) at Dec. 31, 2022			72,169,052
Beginning balance at Dec. 31, 2022		142,055	$ 4	503,708	(361,648)	(9)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Common stock issued for IsoPlexis Merger (in shares)			24,945,611
Common stock issued for IsoPlexis Merger		31,930	$ 1	31,929
Fair value of vested IsoPlexis options attributable to pre-merger service		306		306
Fair value of IsoPlexis warrant at Acquisition Date		170		170
Exercise of stock options (in shares)			78,359
Exercise of stock options		29		29
Vesting of restricted stock units (in shares)			285,129
Employee stock purchase plan (in shares)			121,863
Employee stock purchase plan		166		166
RSUs issued for 2022 Bonuses (in shares)	[1]		1,144,901
RSUs issued for 2022 Bonuses	[1]	2,107		2,107
Stock-based compensation		4,390		4,390
Unrealized gain (loss) on marketable securities		9				9
Foreign currency translation adjustments		(3)				(3)
Net loss		(23,419)			(23,419)
Ending balance (in shares) at Mar. 31, 2023			98,744,915
Ending balance at Mar. 31, 2023		$ 157,740	$ 5	$ 542,805	$ (385,067)	$ (3)
[1]Annual bonuses for certain employees related to fiscal year 2022 were not paid in cash and instead the Company issued fully vested RSUs on March 3, 2023 with a grant date fair value of $1.84 per share. The associated expense was recorded in 2022, the period in which the bonus was earned.

Condensed Consolidated Statem_4

Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2023		Mar. 31, 2022
Cash flows from operating activities:
Net loss	$ (23,419)		$ (21,426)
Adjustments to reconcile net loss to cash used in operating activities:
Depreciation and amortization	2,100		1,944
Stock-based compensation	4,388		5,393
RSUs issued for 2022 Bonuses	2,107	[1]	0
Amortization of operating lease right-of-use assets	852		735
Non-cash interest and other expense related to debt and note receivable agreements	16		16
Provision for doubtful accounts	173		0
Loss on debt extinguishment	162		0
Loss on disposal and impairment of property and equipment	151		28
Realized loss on marketable securities	6		0
Other non-cash	(638)		0
Changes in operating assets and liabilities:
Trade accounts receivable	(3,684)		8,221
Inventory	964		(1,122)
Prepaid expenses, other current assets and other assets	1,865		2,057
Trade accounts payable	5,373		298
Deferred revenue	551		(2,935)
Accrued expenses and other current liabilities	(9,660)		(2,552)
Operating lease liabilities	(860)		(726)
Net cash used in operating activities	(19,553)		(10,069)
Cash flows from investing activities:
Purchase of property and equipment	(414)		(4,375)
Purchase of marketable securities	(2,451)		0
Proceeds from sales of marketable securities	36,749		0
Proceeds from maturities of marketable securities	12,400		0
Asset acquisition	(264)		0
Acquisitions, net of cash acquired	(40,285)		0
Net cash provided by (used in) investing activities	5,735		(4,375)
Cash flows from financing activities:
Repayment of term loan	(20,000)		0
Proceeds from issuance of debt	70,000		0
Payment of debt issuance costs	(1,200)		0
Proceeds from issuance of common stock upon exercise of stock options	29		412
Proceeds from issuance of common stock under employee stock purchase plan	166		610
Net cash provided by financing activities	48,995		1,022
Net increase (decrease) in cash and cash equivalents and restricted cash	35,177		(13,422)
Cash, cash equivalents and restricted cash at beginning of period	86,522		178,366
Cash, cash equivalents and restricted cash at end of period	$ 121,699		$ 164,944
[1]Annual bonuses for certain employees related to fiscal year 2022 were not paid in cash and instead the Company issued fully vested RSUs on March 3, 2023 with a grant date fair value of $1.84 per share. The associated expense was recorded in 2022, the period in which the bonus was earned.

Condensed Consolidated Statem_5

Condensed Consolidated Statements of Changes in Stockholders' Equity (Unaudited) (Parenthetical)	Mar. 03, 2023 $ / shares
Statement of Stockholders' Equity [Abstract]
Issuance of vested RSUs with grant date fair value (in dollars per share)	$ 1.84

The Company and Basis of Presen

The Company and Basis of Presentation	3 Months Ended
	Mar. 31, 2023
Organization, Consolidation and Presentation of Financial Statements [Abstract]
The Company and Basis of Presentation	The Company and Basis of Presentation Description of Business PhenomeX Inc. (the “Company” or “PhenomeX”) is a functional cell biology company that provides live cell biology research tools which deliver deep insights into cellular function and new perspectives on phenomes. PhenomeX and its consolidated subsidiaries are hereinafter referred to as the “Company.” The Company’s headquarters are in Emeryville, California. Basis of Presentation On December 21, 2022, Berkeley Lights, Inc. (“Berkeley Lights”) entered into an Agreement and Plan of Merger (“Merger Agreement”) with Iceland Merger Sub Inc., a wholly owned subsidiary of Berkeley Lights (“Merger Sub”) and IsoPlexis Corporation (“IsoPlexis”). Pursuant to the Merger Agreement on March 21, 2023 (“Acquisition Date”), Merger Sub was merged with IsoPlexis, with IsoPlexis surviving the merger as a wholly owned subsidiary of Berkeley Lights (“IsoPlexis Merger”). The newly combined company has been renamed PhenomeX. The historical financial statements of PhenomeX for periods prior to the IsoPlexis Merger are the historical financial statements of Berkeley Lights. The accompanying unaudited condensed consolidated financial statements (“condensed consolidated financial statements”) have been prepared in accordance with generally accepted accounting principles in the United States of America. In the opinion of the Company’s management, the condensed consolidated financial statements reflect all adjustments, which are normal and recurring in nature, necessary for fair financial statement presentation. The preparation of these condensed consolidated financial statements and accompanying notes requires management to make estimates and assumptions that affect the amounts reported. Actual results could differ materially from those estimates. Liquidity The Company has experienced losses from its operations since its inception and has relied primarily on equity and debt financing to fund its operations to date. For the three months ended March 31, 2023, the Company had a consolidated net loss of $23.4 million and as of March 31, 2023 had an accumulated deficit of $385.1 million. Cash, cash equivalents and marketable securities were $51.6 million as of March 31, 2023. On March 21, 2023, the Company acquired IsoPlexis which also had experienced losses since its inception, and entered into the second amended and restated credit agreement with East West Bank (“EWB”), which increased the Company’s term loan with EWB from $20.0 million to $70.0 million, of which $52.5 million (including prepayment premium and interest) was used to repay indebtedness of IsoPlexis. The second amended and restated credit agreement with EWB requires the Company to maintain $70.0 million of cash in a deposit account with EWB that is assigned to EWB. This deposit is recorded as restricted cash on the Company’s condensed consolidated balance sheet. See Note 12 for additional information on our second amended and restated credit agreement with EWB including the covenants contained therein. These factors raise substantial doubt about the Company’s ability to continue as a going concern within one year after these financial statements are issued. The accompanying financial statements have been prepared on a going concern basis, which contemplates the realization of assets and the settlement of liabilities and commitments in the normal course of business. The financial statements do not reflect any adjustment that might result if the Company is unable to continue as a going concern.

Summary of Significant Accounti

Summary of Significant Accounting Policies	3 Months Ended
	Mar. 31, 2023
Accounting Policies [Abstract]
Summary of Significant Accounting Policies	Summary of Significant Accounting Policies Significant Accounting Policies The Company’s significant accounting policies are disclosed in its Annual Report on Form 10-K for the year ended December 31, 2022 filed with the Securities and Exchange Commission. Updates to those policies are below, including updates related to the IsoPlexis Merger. Cash, cash equivalents and restricted cash The Company considers all highly liquid investments with a maturity of three months or less when purchased to be cash equivalents. The Company records cash and cash equivalents as restricted when it is unable to freely use such cash and cash equivalents for general operating purposes. As of March 31, 2023, restricted cash consisted of $70.0 million in a deposit account with EWB that is assigned to EWB as a result of refinancing the Company’s term loan and $0.1 million related to a letter of credit with an international customer. The following table provides a reconciliation of cash, cash equivalents and restricted cash included in our condensed consolidated balance sheets to the totals presented on the condensed consolidated statements of cash flows (in thousands): March 31, 2023 December 31, 2022 Cash $ 45,015 $ 63,596 Cash equivalents 6,591 22,926 Restricted cash 70,093 — Total cash, cash equivalents and restricted cash as presented on the condensed consolidated statements of cash flows $ 121,699 $ 86,522 Accounts Receivables and Allowance for Credit Losses Trade accounts receivable are recorded at the invoiced amount as a result of the transaction with customers. The Company maintains allowances for credit losses for uncollectible accounts receivable. The Company estimates anticipated losses from doubtful accounts based on days past due, historical collection history, and other factors. Write-offs are recorded at the time all collection efforts have been exhausted. The Company reviews its allowance for doubtful accounts on a quarterly basis. Inventory Inventories are recorded at the lower of cost, determined on a first-in, first-out basis, or net realizable value. Inventory that is obsolete or in excess of forecasted usage is written down to its estimated net realizable value based on assumptions about future demand and market conditions. Inventory write-downs are charged to cost of goods sold and establish a new cost basis for the inventory. Costs included in inventories are raw materials, labor, supplies, allocable depreciation of manufacturing facilities, equipment and overhead. Stock-based compensation The Company maintains the 2020 Incentive Award Plan (“2020 Plan”), an incentive compensation plan under which stock options, restricted stock units (“RSUs”) and restricted stock awards (“RSAs”) are granted to employees, non-employee consultants and directors. Stock-based compensation expense is calculated based on the grant date fair value of the award. The Company determines the fair value of RSUs and RSAs based on the closing price of the Company’s common stock as reported by Nasdaq on the date of the grant. The Company estimates the fair value of the majority of stock option awards on the grant date using the Black-Scholes option-pricing model. For option awards that include a goal tied to the Company share price (i.e. a market condition) the Company uses a Monte Carlo simulation to estimate the fair value. The fair value of stock options, RSUs and RSAs with only a service condition is recognized as compensation expense on a straight-line basis over the requisite service period in which the awards are expected to vest and forfeitures are recognized as they occur. Stock options and RSUs that include a service condition and a performance condition are considered expected to vest when the performance condition is probable of being met. Compensation expense associated with performance awards that are determined to be probable of achievement is recognized over the requisite service period on a tranche-by-tranche basis. For performance stock options and RSUs not initially assessed as probable of achievement, the Company records a cumulative adjustment to compensation expense in the period the Company changes its determination that a performance condition becomes probable of being achieved. The Company ceases recognition of compensation expense in any periods where the Company determines the attainment of a performance condition is no longer probable. If the performance goals are determined to be improbable, any previously recognized compensation expense is reversed. The fair value of stock options with a market condition is recognized over the requisite service period for each tranche of the award and is recognized regardless of whether (or to what extent) the market condition is ultimately achieved. Business Combinations We account for business combinations using the acquisition method of accounting, which generally requires that assets acquired and liabilities assumed be recorded at their fair values as of the Acquisition Date on our Condensed Consolidated Balance Sheets. Any excess of consideration over the fair value of net assets acquired is recorded as goodwill. The determination of estimated fair value requires us to make significant estimates and assumptions. As a result, we may record adjustments to the fair values of assets acquired and liabilities assumed within the measurement period (up to one year from the Acquisition Date) with the corresponding offset to goodwill. Transaction costs associated with business combinations are expensed as they are incurred. Goodwill and Intangible Assets Goodwill represents the excess of the consideration transferred over the estimated fair value of assets acquired and liabilities assumed in a business combination. Intangible assets are measured at their respective fair values as of the Acquisition Date and may be subject to adjustment within the measurement period, which may be up to one year from the Acquisition Date. The Company does not amortize goodwill and intangible assets with indefinite useful lives. Goodwill and indefinite-lived intangible assets are tested for impairment annually, or more frequently if events or changes in circumstances indicate that it is more likely than not that the assets are impaired. Such triggering events potentially warranting an annual or interim goodwill impairment assessment include, among other factors, declines in historical or projected revenue, operating income or cash flows, and sustained decreases in the Company’s stock price or market capitalization. During the three months ended March 31, 2023, the Company experienced a decline in its market capitalization as a result of a sustained decrease in the Company’s stock price. Although the Company only recently acquired goodwill, as the Company operates as a single reporting unit, this sustained decrease was considered to represent a triggering event requiring management to perform a quantitative goodwill impairment test as of March 31, 2023. Refer to Note 8, Goodwill and Other Intangible Assets, for further information. Intangible assets with finite useful lives are amortized over their estimated useful lives, generally on a straight-line basis, and are reviewed for impairment when facts or circumstances indicate that the carrying value of these assets may not be recoverable. Impairment of Long-Lived Assets Long-lived assets, including property, plant and equipment and finite-lived intangible assets, are reviewed for impairment whenever facts or circumstances indicate that the carrying value of an asset may not be recoverable. Should there be an indication of impairment, we test for recoverability by comparing the estimated undiscounted future cash flows expected to result from the use of the asset to the carrying amount of the asset or asset group. If the asset or asset group is determined to be impaired, any excess of the carrying value of the asset or asset group over its estimated fair value is recognized as an impairment loss. Foreign currency translation and transactions The Company assesses the functional currency of each of its international subsidiaries. For subsidiaries where the functional currency is the U.S. dollar, gains or losses arising from currency exchange rate fluctuations on transactions denominated in a currency other than the U.S. dollar are included in other income (expense), net. For subsidiaries where the functional currency is the local currency, the translation of foreign currencies into U.S. dollars is performed for balance sheet accounts using exchange rates in effect at the balance sheet dates and revenue and expense accounts using the average exchange rate during each period. The gains and losses resulting from the translation are included in accumulated other comprehensive income in stockholders’ equity and are excluded from net income. The portions of intercompany accounts receivable and accounts payable that are intended for settlement are translated at exchange rates in effect at the balance sheet date. Research and development state tax credits Research and development (“R&D”) tax credits exchanged for cash pursuant to the Connecticut R&D Tax Credit Exchange Program, which permits a qualified small business engaged in R&D activities within Connecticut to exchange its unused R&D tax credits for a cash amount equal to 65% of the value of exchanged credits, are recorded as a receivable and other income in the year the R&D tax credits relate to, as it is reasonably assured that the R&D tax credits will be received, based upon the Company’s history of filing for and receiving the tax credits. R&D tax credits receivable where cash is expected to be received by the Company more than one year after the balance sheet date are classified as noncurrent in the consolidated balance sheets. The Company has recorded $0.2 million of R&D tax credits receivable as of March 31, 2023. Warrants On March 21, 2023 and in connection with the closing of the IsoPlexis Merger, PhenomeX, IsoPlexis and Perceptive Credit Holdings III, LP (“Perceptive”) executed a warrant certificate to purchase shares of PhenomeX stock (“Warrant Certificate”). The Company accounts for these common stock warrants as equity classified instruments in accordance with ASC 480, Distinguishing Liabilities from Equity.

Marketable Securities

Marketable Securities	3 Months Ended
	Mar. 31, 2023
Investments, Debt and Equity Securities [Abstract]
Marketable Securities	Marketable Securities Short-Term Marketable Securities The Company may invest in available-for-sale marketable debt securities generally consisting of commercial paper and U.S. government securities with contractual maturities due within one year. The following tables summarize the amortized costs and carrying value of the Company’s available-for-sale securities, by balance sheet classification and major security type, as of March 31, 2023 and December 31, 2022 (in thousands): Marketable Securities reported as Cash Equivalents March 31, 2023 Amortized Cost Unrealized Gains Unrealized Losses Fair Value Money market funds $ 6,591 $ — $ — $ 6,591 Total $ 6,591 $ — $ — $ 6,591 December 31, 2022 Amortized Cost Unrealized Gains Unrealized Losses Fair Value Money market funds $ 2,354 $ — $ — $ 2,354 Commercial paper 16,606 — (4) 16,602 U.S. agency securities 3,969 1 — 3,970 U.S. government securities — — — — Total $ 22,929 $ 1 $ (4) $ 22,926 Marketable Securities reported as Short-term Marketable Securities As of March 31, 2023, the Company did not hold any short-term marketable securities. Realized gains/losses from the sale of short-term marketable securities during the three months ended March 31, 2023 were immaterial. Short-term marketable securities at December 31, 2022 were as follows (in thousands): December 31, 2022 Amortized Cost Unrealized Gains Unrealized Losses Fair Value Commercial paper $ 22,158 $ 1 $ (11) $ 22,148 U.S. agency securities 4,941 1 — 4,942 U.S. government securities 19,159 5 (2) 19,162 Total $ 46,258 $ 7 $ (13) $ 46,252 At each reporting date, the Company performs an evaluation of impairment to determine if any unrealized losses are the result of credit losses. Impairment is assessed at the individual security level. Unrealized losses on available-for-sale debt securities as of December 31, 2022 were not significant and were primarily market driven due to changes in interest rates, and not due to increased credit risk associated with specific securities. Accordingly, the Company did not record an allowance for credit losses on these short term investments as of December 31, 2022. See Note 9 for information about the fair value of the Company’s short-term marketable securities.

Significant Risks and Uncertain

Significant Risks and Uncertainties Including Business and Credit Concentrations	3 Months Ended
	Mar. 31, 2023
Risks and Uncertainties [Abstract]
Significant Risks and Uncertainties Including Business and Credit Concentrations	Significant Risks and Uncertainties Including Business and Credit Concentrations Financial instruments that potentially subject the Company to concentrations of credit risk consist primarily of cash equivalents, short-term available-for-sale debt securities and trade receivables. The Company invests its excess cash in money market funds and short-term available-for-sale debt securities with the primary objective of facilitating liquidity and capital preservation. The Company has established guidelines relative to credit ratings, diversification and maturities that seek to maintain safety and liquidity. Deposits in financial institutions may exceed the amounts of insurance provided on such deposits. To date, the Company has not experienced any material realized losses on its deposits of cash, cash equivalents and marketable securities. The Company controls credit risk through credit approvals and monitoring procedures. The Company performs periodic credit evaluations of its customers and generally does not require collateral. Accounts receivable are recorded net of an allowance for doubtful accounts. The allowance for doubtful accounts is based on management’s assessment of the collectability of specific customer accounts and the aging of the related invoices and represents the Company’s best estimate of expected credit losses in its existing trade accounts receivable. At March 31, 2023, the Company recorded an allowance for doubtful accounts of $0.9 million. At December 31, 2022 , the Company had not recorded any material allowance for doubtful accounts. For the three months ended March 31, 2023, three customers accounted for 39%, 10% and 10% of revenue. For the three months ended March 31, 2022, three customers accounted for 18%, 13% and 10% of revenue.

Business Combinations

Business Combinations	3 Months Ended
	Mar. 31, 2023
Business Combination and Asset Acquisition [Abstract]
Business Combinations	Business Combinations IsoPlexis Merger On March 21, 2023, the Company completed the IsoPlexis Merger. Under the terms of the Merger Agreement, IsoPlexis shareholders received, for each share of IsoPlexis stock, 0.612 shares of Berkeley Lights common stock (which was automatically converted into shares of PhenomeX common stock). Consideration Transferred The Acquisition Date fair value of consideration transferred in the IsoPlexis Merger totaled $84.9 million, summarized as follows (in thousands): Fair value of PhenomeX common stock issued to IsoPlexis stockholders (1) $ 31,930 Repayment of IsoPlexis debt (2) 52,482 Fair value of vested IsoPlexis options attributable to pre-merger service (3) 306 Fair value of IsoPlexis warrant at Acquisition Date (4) 170 Total purchase consideration $ 84,888 (1) Represents the fair value of PhenomeX common stock issued to IsoPlexis stockholders pursuant to the Merger Agreement. The fair value is based on 24,945,611 shares of PhenomeX common stock at $1.28 per share on March 21, 2023 issued to IsoPlexis stockholders. IsoPlexis stockholders received 0.612 shares of PhenomeX stock for each IsoPlexis share they held. (2) Represents $50 million in principal repayment to retire debt of IsoPlexis, as required by change in control provisions of the debt, as well as prepayment penalties and accrued interest. (3) Represents the fair value at March 21, 2023 of IsoPlexis options assumed by PhenomeX attributable to pre-combination service (see Note 13 for additional information). (4) Represents the fair value of the IsoPlexis warrant assumed by PhemoneX at March 21, 2023 (see Note 13 for additional information). Fair Value of Assets Acquired and Liabilities Assumed The Company accounted for the IsoPlexis Merger as a business combination. The identifiable assets acquired and liabilities assumed were recorded at their preliminary fair values as of the Acquisition Date and are consolidated into our financial statements. The assignment of fair market value requires significant judgments regarding the estimates and assumptions used to value the acquired assets and liabilities assumed. For the preliminary fair values of the assets acquired and liabilities assumed, we utilized the cost, income and market approaches from the perspective of a market participant. The following table summarizes the preliminary fair values for each major class of assets acquired and liabilities assumed at the Acquisition Date (in thousands). The Company used third party valuation professionals to aid in the determination of the estimated fair value of certain assets acquired and liabilities assumed. The Company is in the process of finalizing the purchase price allocation associated with this transaction. As such, the preliminary purchase allocation set forth below is subject to revision as additional information is obtained and the valuation process is completed. Cash and cash equivalents $ 12,197 Accounts receivable 3,075 Inventories 27,287 Prepaid expenses and other current assets 4,190 Property and equipment, net 11,206 Intangible assets 22,900 Goodwill 12,246 Operating lease right-of-use assets 4,975 Other assets 526 Total assets acquired 98,602 Accounts payable 2,367 Accrued expenses and other current liabilities 4,912 Deferred revenue 1,399 Operating lease obligations 5,036 Total liabilities assumed 13,714 Total consideration transferred $ 84,888 Acquired Receivables The fair value of assets acquired includes accounts receivable of $3.1 million, which is net of an associated allowance for credit losses of $0.7 million. Inventory The fair value of inventory acquired was $27.3 million, which included a step up of $4.9 million from the book value as a result of the valuation at the Acquisition Date. The original cost basis of the inventory acquired from IsoPlexis was $22.4 million, which was net of a reserve for excess and obsolete inventory of $15.4 million. Intangible Assets and Goodwill Intangible assets includes $11.7 million of patented technology, $7.7 million of customer relationships and $3.5 million of IsoPlexis trade names and trademarks. The intangible assets will be amortized over their respective useful lives which range from eight Transaction Costs The Company recognized transaction costs associated with the IsoPlexis Merger of $3.5 million for the three months ended March 31, 2023 plus $2.8 million which was recognized in the fourth quarter of 2022. These costs are primarily related to professional services and are recorded in “Selling, general, and administrative” expenses in the Company’s condensed consolidated statement of operations. Supplemental Pro Forma Information The following unaudited pro forma financial information gives effect to the IsoPlexis Merger as if it had been completed on January 1, 2022. The unaudited pro forma information was prepared in accordance with the requirements of ASC 805, which is a different basis than pro forma information prepared under Article 11 of Regulation S-X (“Article 11”). As such, they are not directly comparable with historical results for stand-alone Berkeley Lights prior to March 21, 2023 or our previously provided pro forma financials prepared in accordance with Article 11. The pro forma adjustments are based on historical reported transactions by the respective companies and do not include any anticipated synergies or other expected benefits of the acquisition. (in thousands) Three months ended March 31, 2023 Three months ended March 31, 2022 Total revenue $ 20,170 $ 25,117 Net loss $ (66,463) $ (50,419) Pro forma adjustments consisted of: • Amortization/Depreciation- Tangible and intangible assets are assumed to be recorded at their assigned fair values as of January 1, 2022. Historical depreciation and amortization for IsoPlexis has been removed and the new fair values of the assets are depreciated or amortized over their estimated useful lives. • Interest Expense- Entry into the Second Amended Term Loan and repayment of the Perceptive Credit Agreement are assumed to have occurred on January 1, 2022. Historical interest expense has been removed and replaced with the applicable interest rate as of March 21, 2023 associated with the Second Amended Term Loan, which was 8.5%. • Transaction costs- Both entities incurred transaction costs, which totaled $13.7 million. Of the $13.7 million, approximately $4.4 million was incurred in the first quarter of 2023 and has been eliminated as it is not recurring. • Accounting policies adjustment- IsoPlexis historically classified certain operations, quality and facility related costs in selling, general and administrative expenses. To align with PhenomeX accounting policies, these costs were reclassified to costs of goods sold or research and development. However, since this is a reclassification between expense line items on the statement of operations, the adjustment does not have an impact on revenue or net loss for purposes of the pro forma financial information disclosed above. For the period subsequent to the Acquisition Date, IsoPlexis contributed total revenues and operating loss of $1.0 million and $1.1 million, respectively, for the three months ended March 31, 2023, that were included in the Company’s Condensed Consolidated Statements of Operations. In addition, the Company signed an agreement to license, on an exclusive and perpetual basis, certain intellectual property acquired in the IsoPlexis Merger for $7.3 million (See Note 6 for additional information).

Revenue From Contracts With Cus

Revenue From Contracts With Customers	3 Months Ended
	Mar. 31, 2023
Revenue from Contract with Customer [Abstract]
Revenue From Contracts With Customers	Revenue From Contracts With Customers The Company’s revenue consists of both product revenue and service and other revenue, which is primarily generated through the following revenue streams: (i) platform, (ii) recurring and (iii) partnership, license and other. The Company in the first quarter entered into a license arrangement whereby certain patents were licensed to a third party and for which the customer agreed to pay a non-refundable fee. For licenses of intellectual property the Company recognizes revenue from non-refundable fees when the license is transferred to the customer and the customer is able to use and benefit from the license. The following tables provide an overview of the Company’s revenue streams and how the Company reports revenue in its consolidated statements of operations: Income Statement Classification Product or Service sold Revenue Stream Product revenue Sale of advanced automation systems (Beacon and Lightning systems, Culture Station) Platform Software and workflow licenses Platform Fixed term sales-type lease arrangements with qualified customers Platform Quarterly workflow subscriptions, annual or multi-year subscriptions arrangements (e.g. TechAccess) Recurring Consumables and reagent kits (e.g. OptoSelect chips) Recurring Service and other revenue Strategic partnerships, joint development and collaboration agreements where we provide services for development of new workflows, cells or organism types Partnership, License and Other Application support, installation and training Platform Fixed fee extended warranty and service programs Recurring IP license revenue Partnership, License and Other (1) (1) License revenue relates to certain intellectual property acquired in the IsoPlexis Merger and subsequently licensed to a third party. License revenue related to our platforms (e.g. workflow licenses) is reported as Platform product revenue. The following tables provide information by revenue stream for the periods presented: Three Months Ended March 31, 2023 (in thousands) Product Service and other Total Platform $ 5,773 $ 330 $ 6,103 Recurring 2,605 2,558 5,163 Partnership, License and Other (1) — 7,250 7,250 Total revenue $ 8,378 $ 10,138 $ 18,516 (1) During the three months ended March 31, 2023, the Company signed an agreement to license, on an exclusive and perpetual basis, certain intellectual property acquired in the IsoPlexis Merger for $7.3 million (“License Agreement”). As the $7.3 million represented a non-refundable fee and the license was transferred to the customer during the quarter, the $7.3 million was recognized as revenue during the quarter, which represents all the Partnership, License, and Other revenue during the quarter. Three Months Ended March 31, 2022 (in thousands) Product Service and other Total Platform $ 6,747 $ 657 $ 7,404 Recurring 3,027 2,416 5,443 Partnership, License and Other — 7,359 7,359 Total revenue $ 9,774 $ 10,432 $ 20,206 Revenues by geographical markets are presented in Note 19. Performance Obligations A significant number of the Company’s product and service sales, as well as its feasibility study arrangements, are short-term in nature with a contract term of one year or less. For those contracts, the Company has utilized the practical expedient in ASC 606-10-50-14 exempting the Company from disclosure of the transaction price allocated to remaining performance obligations if the performance obligation is part of a contract that has an original expected duration of one year or less. As of March 31, 2023, the aggregate amount of remaining performance obligations that are unsatisfied or partially unsatisfied related to customer contracts in excess of one year w as $12.0 million, which, to the extent invoiced, is included in deferred revenue on the Company’s condensed consolidated balance sheets, of which approximately 50% is e xpected to be recognized as revenue in the next 12 months, with the remainder recognized afterwards. Contract Balances The following table provides information about receivables, contract assets and deferred revenue from contracts with customers (in thousands): March 31, December 31, Trade accounts receivable, net $ 25,119 $ 18,534 Contract assets, which are included in “Prepaid expenses and other current assets” $ 367 $ 1,283 Contract assets, long-term, which are included in “Other assets” $ 514 $ 549 Deferred revenue (current) $ 10,746 $ 9,092 Deferred revenue (non-current) $ 1,259 $ 963 The contract liabilities of $12.0 million and $10.1 million as of March 31, 2023 and December 31, 2022, respectively, consisted of deferred revenue related to extended warranty service agreements, strategic partnerships and services agreements and advanced automation systems arrangements. Revenue recorded during the three months ended March 31, 2023 i ncluded $2.8 million of previously deferred revenue that was included in contract liabilities as of December 31, 2022. Sales-type Lease Arrangements The Company also enters into sales-type lease arrangements with certain qualified customers. Revenue related to lease elements from sales-type leases is presented as product revenue and was none for the three months ended March 31, 2023 and 2022. The following table presents the future maturity of the Company’s fixed-term customer leases and reconciles the undiscounted cash flows from the amounts due from customers under such arrangements as of March 31, 2023 (in thousands): Year ending December 31, Sales-Type Remainder of 2023 (1) $ 334 2024 445 2025 408 2026 — Total undiscounted cash flows 1,187 Less: unearned income (171) Total amounts due from customers (2) $ 1,016 (1) During the three months ended March 31, 2023, the Company impaired the net investment of a sales type lease with a customer. The write down of the respective contract asset of $0.8 million, net of the return of the underlying asset, was recorded as an impairment charge of $0.6 million within selling, general and administrative expense in the Company’s condensed consolidated statement of operations and the resulting return of the underlying asset was recorded as an addition to fixed assets in the Company’s condensed consolidated balance sheet.

Balance Sheet Accounts

Balance Sheet Accounts	3 Months Ended
	Mar. 31, 2023
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Balance Sheet Accounts	Balance Sheet Accounts Trade accounts receivable, net consists of the following (in thousands): March 31, December 31, Trade accounts receivable $ 26,013 $ 18,534 Allowance for doubtful accounts (894) — Total $ 25,119 $ 18,534 Changes in the allowance for doubtful accounts were as follows (in thousands): Three months ended March 31, 2023 Allowance for doubtful accounts, beginning of year $ — Allowance assumed in IsoPlexis Merger (721) Write-offs of uncollectible accounts — Provision for doubtful accounts (173) Allowance for doubtful accounts, end of period $ (894) Inventory The following table shows the components of inventory (in thousands): March 31, December 31, Raw materials $ 32,816 $ 11,946 Work in progress 1,106 — Finished goods 11,617 6,915 Total $ 45,539 $ 18,861 Prepaid expenses and other current assets The following table shows the components of prepaid expenses and other current assets (in thousands): March 31, December 31, Contract asset $ 367 $ 1,283 Vendor deposits 421 126 Deferred costs 365 472 Prepaid insurance 3,534 2,025 Other (1) 4,691 2,877 Total $ 9,378 $ 6,783 (1) Other includes primarily prepaid rent expenses, software licenses and prepaid VAT. Accrued expenses and other current liabilities The following table shows the components of accrued expenses and other current liabilities (in thousands): March 31, December 31, Accrued payroll and employee related expenses $ 6,611 $ 7,410 Lease liability – short-term 4,958 3,291 Accrued product warranty 788 749 Accrued legal expenses 5,499 8,271 Other (1) 1,789 1,619 Total $ 19,645 $ 21,340 (1) Other includes accrued income taxes, sales taxes, accrued royalties and other miscellaneous accruals.

Goodwill and Other Intangible A

Goodwill and Other Intangible Assets	3 Months Ended
	Mar. 31, 2023
Goodwill and Intangible Assets Disclosure [Abstract]
Goodwill and Other Intangible Assets	Goodwill and Other Intangible Assets Goodwill On March 21, 2023, the Company completed the IsoPlexis Merger. Under the purchase method of accounting, the Company preliminarily recorded the $12.2 million excess of the Acquisition Date fair value of the consideration transferred over the estimated fair value of net tangible and identifiable intangible assets that it acquired as goodwill. At March 31, 2023, the carrying amount of this goodwill was $12.2 million. During the three months ended March 31, 2023, the Company experienced a decline in its market capitalization as a result of a sustained decrease in the Company’s stock price. The Company considered such sustained decrease to represent a triggering event requiring management to perform a quantitative goodwill impairment test as of March 31, 2023. Based on the results of the quantitative goodwill impairment test, it was concluded that the estimated fair value of the Company’s reporting unit was greater than its carrying value, as such, the Company did not record a goodwill impairment charge during the three months ended March 31, 2023. In future periods, if the Company were to experience a further decline in its market capitalization or expected results for a sustained period of time, the Company may be required to perform an additional quantitative goodwill impairment assessment at an interim or annual period and could be required to recognize a non-cash goodwill impairment charge at that time, which could be material. Acquired Intangible Assets In connection with the IsoPlexis Merger, the Company identified certain intangible assets summarized in the table below (see Note 5 for further information). In addition, on February 15, 2023, the Company acquired certain tangible and intangible assets from Evorion Biotechnologies for a total purchase price of $0.3 million, of which $0.2 million related to intangible assets attributable to patents and technology. These intangible assets are also included in the table below. March 31, 2023 (in thousands): Remaining Useful Life (Years) Gross Accumulated Amortization Net Customer relationships 8 $ 7,700 $ (5) $ 7,695 Trade names 10 3,500 (11) 3,489 Patented technology 14 11,911 (23) 11,888 Total intangible assets $ 23,111 $ (39) $ 23,072 Amortization expense was $39,000 for the three months ended March 31, 2023. In connection with the License Agreement, the Company reviewed the patented technology intangible for indicators of impairment, noting that the patented technology was valued using the relief from royalty approach based on projected revenues from products and services of IsoPlexis, which did not contemplate the License Agreement. In addition, the Company still owns, and retains certain rights to, the intellectual property that was licensed under the License Agreement. Accordingly the Company concluded that an impairment was not necessary. The estimated annual amortization of intangible assets for the remainder of 2023 and the next four years is presented in the table below (in thousands). Actual amortization expense to be reported in future periods could differ from these estimates as a result of the finalization of the preliminary purchase price allocation of the IsoPlexis Merger, divestitures and other factors. March 31, 2023 Year Ending December 31: Remainder of 2023 $ 1,689 2024 $ 2,163 2025 $ 2,163 2026 $ 2,163 2027 $ 2,163

Fair Value of Financial Instrum

Fair Value of Financial Instruments	3 Months Ended
	Mar. 31, 2023
Fair Value Disclosures [Abstract]
Fair Value of Financial Instruments	Fair Value of Financial Instruments The following is a description of the valuation techniques the Company uses to measure the fair value of assets and reports fair value on a recurring basis: • Cash equivalents: At March 31, 2023, the Company’s cash equivalents consisted of money market funds. Money market funds are highly liquid investments and are actively traded and pricing information is readily available. Accordingly, the Company classifies these securities as Level 1 of the fair value hierarchy. • Short Term Marketable Securities: At March 31, 2023, the Company did not hold any short term marketable securities. Generally, the Company values short-term marketable securities using quoted prices in active markets for similar instruments. Accordingly, the Company classifies marketable securities as Level 2 of the fair value hierarchy. The carrying amounts of the Company’s cash, accounts receivable, prepaid expenses, other current assets, accounts payable, accrued expenses and other current liabilities as of March 31, 2023 and December 31, 2022 approximate fair value due to their relatively short maturities. At March 31, 2023 and December 31, 2022, the fair value measurements of the Company’s assets measured on a recurring basis were as follows: (in thousands): March 31, Quoted Prices Significant Significant Cash equivalents: Money market funds $ 6,591 $ 6,591 $ — $ — Total assets measured at fair value $ 6,591 $ 6,591 $ — $ — December 31, Quoted Prices Significant Significant Cash equivalents: Money market funds $ 2,354 $ 2,354 $ — $ — Commercial paper 16,602 — 16,602 — U.S. agency securities 3,970 — 3,970 — Total cash equivalents 22,926 2,354 20,572 — Debt securities, available for sale: Commercial paper 22,148 — 22,148 — U.S. agency securities 4,942 — 4,942 — U.S. government securities 19,162 — 19,162 — Total debt securities, available for sale 46,252 — 46,252 — Total assets measured at fair value $ 69,178 $ 2,354 $ 66,824 $ — The carrying values and fair values of the Company’s financial instruments not measured at fair value were as follows (in thousands): March 31, 2023 December 31, 2022 Carrying Fair Value Carrying Fair Value Long-term debt, including current maturities $ 68,886 $ 70,000 $ 19,826 $ 17,443 The Company estimated the fair value of its long-term debt using a market-based approach that considers an average cost of debt. The Company has incorporated its own credit risk for all liability fair value measurements. Such fair value measurements are considered Level 2 under the fair value hierarchy. The Company did not have any transfers of financial assets measured at fair value on a recurring basis between the levels of the fair value measurement hierarchy during the periods presented.

Property and Equipment, net

Property and Equipment, net	3 Months Ended
	Mar. 31, 2023
Property, Plant and Equipment [Abstract]
Property and Equipment, net	Property and Equipment, net Property and equipment, net comprised the following (in thousands): March 31, December 31, Equipment, tooling and molds $ 47,577 $ 36,152 Computer software and equipment 8,037 2,667 Furniture, fixtures and other 2,600 2,007 Leasehold improvements 12,509 10,836 Construction in process 1,370 1,409 Total property and equipment 72,093 53,071 Less: Accumulated depreciation (38,251) (29,224) Property and equipment, net (1) $ 33,842 $ 23,847 (1) Property and equipment, net at each of March 31, 2023 and December 31, 2022 includes $0.1 million of assets held for sale. During the three months ended March 31, 2023 and 2022 losses on the impairment and disposal of property and equipment were not material.

Leases

Leases	3 Months Ended
	Mar. 31, 2023
Leases [Abstract]
Leases	Leases The Company leases office, manufacturing, distribution and laboratory facilities in various locations in the United States, primarily in Emeryville, California and Branford, Connecticut. The Company also leases facilities in Shanghai, China for office and laboratory facilities. On December 28, 2022, the Company entered into a sub-lease arrangement for its facility in Lexington, Massachusetts. Sub-lease income for the three months ended March 31, 2023 was $0.1 million and was recorded as an offset to rent expense. Future payments associated with the Company’s operating lease liabilities as of March 31, 2023 are as follows (in thousands): Operating leases Undiscounted lease payments for the year ending December 31, Remainder of 2023 $ 4,691 2024 6,297 2025 5,952 2026 5,398 2027 4,759 Thereafter 7,464 Total undiscounted lease payments 34,561 Less: implied interest (4,304) Less: tenant improvement allowances receivable (65) Present value of operating lease payments 30,192 Less: current portion (1) (4,958) Total long-term operating lease liabilities $ 25,234 (1) Included in the balance sheet caption “Accrued expenses and other current liabilities.” Rent expense, net for the three months ended March 31, 2023 and 2022 was $0.9 million and $1.1 million, respectively. Under the terms of the lease agreements, the Company is also responsible for certain variable lease payments that are not included in the measurement of the lease liability. Variable lease payments for operating leases were $0.8 million and $0.8 million for the three months ended March 31, 2023 and 2022, respectively, including non-lease components such as common area maintenance fees. The following information represents supplemental disclosure for the statement of cash flows related to operating leases (in thousands): Three months ended March 31, 2023 Three months ended March 31, 2022 Right-of-use assets obtained for new operating lease liabilities $ — $ — Right-of-use lease assets assumed in IsoPlexis Merger $ 4,975 $ — Cash paid for amounts included in the measurement of lease liabilities $ 989 $ 1,098 The following summarizes additional information related to operating leases: March 31, 2023 December 31, 2022 Weighted-average remaining lease term (years) 5.71 6.48 Weighted-average discount rate 4.73 % 4.66 %

Long-Term Debt

Long-Term Debt	3 Months Ended
	Mar. 31, 2023
Debt Disclosure [Abstract]
Long-Term Debt	Long-term Debt On May 23, 2018, the Company entered into a Loan and Security Agreement (“Loan Agreement”) with EWB to provide a $20.0 million term loan facility (“Term Loan”). The loan facility was fully drawn as of May 23, 2018. On June 30, 2021, the Company entered into an Amended and Restated Loan and Security Agreement (“Amended Loan Agreement”) with EWB. Pursuant to the Amended Loan Agreement, EWB provided a $20.0 million term loan (“Amended Term Loan”) which was used to refinance the Term Loan outstanding under the Loan Agreement dated May 23, 2018. The Amended Term Loan had a maturity of 48 months and a fixed interest rate of 4.17% . In addition, the Amended Term Loan had an initial interest-only period of 24 months, which could have been extended to up to 36 months based on the achievement of certain liquidity measures, and could have been pre-paid without penalty at any time. On March 21, 2023, the Company entered into a Second Amended and Restated Loan and Security Agreement (“Second Amended Loan Agreement”) with EWB. Pursuant to the Second Amended Loan Agreement, EWB increased the existing Amended Term Loan amount of $20.0 million by $50.0 million to an aggregate outstanding principal of $70.0 million (“Second Amended Term Loan”). The Company used the proceeds from the Second Amended Term Loan to repay $52.5 million of indebtedness (including prepayment premium and interest) with Perceptive held by IsoPlexis (“Perceptive Credit Agreement”). Associated with these transactions, a $0.2 million loss on extinguishment of debt and a $0.7 million commitment fee associated with the Loan Agreement, was recorded in Other expense, net on our condensed consolidated statement of operations during the three months ended March 31, 2023. The Second Amended Term Loan has a maturity of 60 months and bears interest at a variable rate per annum equal to (i) the greater of 6.25% or the variable rate of interest, per annum, most recently announced by EWB as its prime rate, plus (ii) one-half of one percent (0.5%). In addition, the Second Amended Term Loan has an initial interest-only period of 24 months, which can be extended up to two times, each by an additional six months, if certain EBITDA tests as set forth in the Second Amended Loan Agreement are satisfied. The Second Amended Term loan carries a prepayment penalty equal to one percent (1%) of the amount of any prepayment of the outstanding balance, if the prepayment is made before the first anniversary of the loan closing date. The Second Amended Loan Agreement was accounted for as a debt extinguishment and the Company capitalized incremental debt issuance costs. The Second Amended Term Loan is guaranteed by certain domestic subsidiaries of the Company (such subsidiaries, together with the Company, the “Credit Parties”). The Second Amended Loan Agreement grants EWB a security interest in and liens on substantially all assets of the Company and the other Credit Parties, excluding intellectual property, provided, that if the Company does not satisfy a liquidity test set forth in the Second Amended Loan Agreement, the Credit Parties will be required to grant a first-priority security interest in their intellectual property. In addition, certain other terms of the original agreements as previously in effect were amended by the Second Amended Loan Agreement, including certain financial covenants. For example, the Company must maintain cash and cash equivalents of no less than $70.0 million in the aggregate at all times in a deposit account with EWB that is assigned to EWB. As a result, the deposit of $70.0 million was recorded as restricted cash on the Company’s condensed consolidated balance sheet. In addition, if the Company’s cash and cash equivalents balance at EWB falls below $100.0 million, the Company is then required to maintain specific minimum EBITDA amounts at all times thereafter. The Second Amended Loan Agreement contains customary affirmative and negative covenants, including limitations on mergers, asset sales, liens, investments and indebtedness. See Exhibit 10.1 for the Second Amended Loan Agreement. As of March 31, 2023, the Company was in compliance with the terms and covenants of the Agreement. The following is a schedule of payments due on notes payable as of March 31, 2023 (in thousands): March 31, Year Ending December 31: Remainder of 2023 $ 4,545 2024 6,049 2025 13,680 2026 15,437 2027 14,532 2028 41,990 Total payments due 96,233 Less: Interest payments, loan discounts and financing costs (27,347) Current portion, less loan discounts and financing costs — Notes payable, net of current portion $ 68,886

Equity and Stock Compensation P

Equity and Stock Compensation Plans	3 Months Ended
	Mar. 31, 2023
Share-Based Payment Arrangement [Abstract]
Equity and Stock Compensation Plans	Equity and Stock Compensation Plans IsoPlexis Merger On March 21, 2023, in connection with the completion of the IsoPlexis Merger: • All outstanding IsoPlexis RSAs were assumed by PhenomeX and converted into PhenomeX RSAs based on the 0.612 conversion ratio (see Note 5) and on the same terms and conditions (including with respect to vesting schedules and restrictions) as applied to IsoPlexis RSAs immediately prior to the closing of the IsoPlexis Merger. • All outstanding IsoPlexis stock options (whether vested or unvested) that had a per share exercise price of less than $1.28 and were held by continuing employees were assumed by PhenomeX and converted into PhenomeX stock options based on the 0.612 conversion ratio (and rounded down) and on the same terms and conditions (including with respect to time-based vesting) as applied to IsoPlexis stock options immediately prior to the closing of the IsoPlexis Merger, with the exercise price per share of the assumed stock options determined by dividing the per share exercise price of the IsoPlexis options by the 0.612 conversion ratio (and rounded up to the nearest whole cent). The assumed stock options expire 10 years from their original date of grant. The assumed stock options and RSAs generally vest 25% upon the one-year anniversary of the service inception date and then ratably each month over the remaining 36 months. On March 21, 2023, PhenomeX assumed 304,619 IsoPlexis RSAs and 378,767 IsoPlexis stock options after applying the 0.612 conversion ratio. The Company accounted for the assumed equity awards as a modification under ASC 718 and recorded stock compensation expense of $0.1 million during the three months ended March 31, 2023 associated with the modification. Future grants of equity awards will be issued under the Company’s 2020 Plan. Warrant Certificate On March 21, 2023 and in connection with the closing of the IsoPlexis Merger, PhenomeX, IsoPlexis and Perceptive executed the Warrant Certificate. Under the Warrant Certificate, the outstanding warrant (“IsoPlexis Warrant”) to purchase shares of common stock, par value $0.001, of IsoPlexis (“IsoPlexis Common Stock”), issued by IsoPlexis to Perceptive was assumed by PhenomeX and converted into a warrant (“PhenomeX Warrant”) to purchase shares of common stock, par value $0.00005, of PhenomeX (“PhenomeX Common Stock”), on the same terms and subject to the same conditions as were applicable to the IsoPlexis Warrant as of immediately prior to the Acquisition Date; provided, that the PhenomeX Warrant is exercisable for 496,560 shares of PhenomeX Common Stock (i.e., a number of shares of PhenomeX Common Stock equal to the number of shares of IsoPlexis Common Stock that were subject to the IsoPlexis Warrant multiplied by the 0.612 exchange ratio and has an exercise price of $9.80 per share of PhenomeX Common Stock (i.e., the exercise price per share of IsoPlexis Common Stock that was applicable to the IsoPlexis Warrant divided by 0.612). Restricted stock awards As a result of the IsoPlexis Merger and discussed above, the Company now has RSAs outstanding. RSAs are rights to receive shares of the Company’s Common Stock upon meeting specified vesting requirements. The fair value of a RSA is the market value as determined by the closing price of the Company’s stock on the original grant date. Stock-based compensation Stock-based compensation related to the Company’s stock-based awards was recorded as an expense and allocated as follows (in thousands): Three months ended March 31, 2023 2022 Cost of sales $ 16 $ 51 Research and development 548 1,581 Selling, general and administrative 3,824 3,761 Total stock-based compensation $ 4,388 $ 5,393

Restructuring

Restructuring	3 Months Ended
	Mar. 31, 2023
Restructuring and Related Activities [Abstract]
Restructuring	Restructuring During 2022, the Company adopted a new strategic plan with the intention of reducing costs and better aligning the organization with the Company’s long-term goals. As a result, the Company approved a set of restructuring initiatives in 2022 and continued with similar initiatives in the first quarter of 2023. During the three months ended March 31, 2023, the Company incurred restructuring charges of $1.3 million, related to severance and other employee-related restructuring costs associated with the termination of approximately 16% of total full-time employees. As of March 31, 2023, the Company has not fully completed its restructuring efforts. It is unable to currently estimate future restructuring charges, but will record any additional restructuring-related expenses as they are incurred. Changes in the Company’s restructuring liability are set forth in the table below (in thousands): Employee severance and termination benefits Non labor restructuring Total Accrual at January 1, 2023 $ 130 $ 107 $ 237 Restructuring liability assumed in IsoPlexis Merger 834 — 834 Restructuring charges 1,290 — 1,290 Cash payments (1,010) (107) (1,117) Non-cash settlements — — — Accrual at March 31, 2023 $ 1,244 $ — $ 1,244 Restructuring liabilities are included in accrued expenses and other current liabilities in the condensed consolidated balance sheet.

Income Taxes

Income Taxes	3 Months Ended
	Mar. 31, 2023
Income Tax Disclosure [Abstract]
Income Taxes	Income TaxesThe Company’s provision for income taxes was $20,000 for the three months ended March 31, 2023 and $20,000 and for the three months ended March 31, 2022. For the three months ended March 31, 2023 and 2022, income from operations before taxes consisted of amounts related to U.S. operations and the Company’s foreign operations. The Company maintains a full valuation allowance on its deferred tax assets, and intends to do so until there is sufficient evidence to support the reversal of all or some portion of this allowance.

Statements of Cash Flows

Statements of Cash Flows	3 Months Ended
	Mar. 31, 2023
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Statements of Cash Flows	Statements of Cash Flows The supplemental cash flow information consists of the following (in thousands): Three months ended March 31, 2023 2022 Cash paid for interest $ 439 $ 137 Cash paid for income taxes $ 19 $ — Non-cash investing and financing activities Non-cash consideration for the acquisition of IsoPlexis $ 32,406 $ — Property and equipment transferred to inventory $ 352 $ — Customer return of Beacon transferred to property and equipment (1) $ 201 $ — Change in accounts payable and accrued liabilities related to purchases of property and equipment $ 684 $ 482 (1) Refer to Note 6 under “Sales-type Lease Arrangements” for further information.

Commitment and Contingencies

Commitment and Contingencies	3 Months Ended
	Mar. 31, 2023
Commitments and Contingencies Disclosure [Abstract]
Commitments and Contingencies	Commitments and Contingencies Legal Proceedings From time to time, the Company may be involved in legal and administrative proceedings and claims of various types. The Company records a liability in its financial statements for these matters when a loss is known and considered probable and the amount can be reasonably estimated. The Company does not recognize gain contingencies until they are realized. Legal costs incurred relating to loss contingencies are expensed as incurred. AbCellera Biologics Litigation In July through September 2020, AbCellera Biologics Inc. (“AbCellera”) filed a series of complaints in the United States District Court for the District of Delaware, alleging that the Company infringed and continues to infringe, directly and indirectly, the following patents exclusively licensed by AbCellera by making, using, offering for sale, selling and/or importing the Company’s Beacon and Culture Station instruments and the OptoSelect chips, and sale of the Opto Plasma B Discovery Workflow: U.S. Patent Nos. 10,107,812, 10,274,494, 10,466,241, 10,578,618, 10,697,962, 10,087,408, 10,421,936, 10,704,018, 10,718,768, 10,738,270, 10,746,737, 10,753,933, 10,775,376, 10,775,377, and 10,775,378. The University of British Columbia (“UBC”), the owner of the patents, joined AbCellera as a named plaintiff in the lawsuits. AbCellera and UBC are seeking, among other things, judgment of infringement, a permanent injunction and damages (including lost profits, a reasonable royalty, reasonable costs and attorney’s fees, and treble damages for willful infringement). In addition to procedural motions, the Company has filed an answer and counterclaims in response to each of the lawsuits. The Company’s counterclaims in each lawsuit include counts for declaratory judgment of non-infringement of the asserted patents, for declaratory judgment of invalidity of the asserted patents, for declaratory judgment of unenforceability of the asserted patents due to inequitable conduct, and unfair competition under state and federal law. The Company filed a motion to transfer the lawsuits to the United States District Court for the Northern District of California, which was granted and where the lawsuits have been consolidated and are now pending (“Consolidated Lawsuit”). On May 6, 2021 and pursuant to Court Order, AbCellera and UBC reduced, without prejudice, the asserted patents in the consolidated lawsuit to the following: US Patent Nos. 10,087,408, 10,421,936, 10,738,270, 10,697,962, 10,753,933, 10,775,376 and 10,775,378. On July 1, 2021, the court issued a Case Management Order that, among other things, requires AbCellera and UBC to further reduce the number of asserted patents to no more than two, and the total asserted patent claims to no more than four per patent prior to the trial. In July 2021 and August 2021, the Company filed petitions for Inter Partes Review (“IPR”) with the Patent Trial and Appeal Board (“PTAB”) of the United States Patent & Trademark Office (“USPTO”), challenging the validity of various asserted claims of U.S. Patent No. 10,087,408 and all asserted claims of U.S. Patent Nos. 10,421,936 and 10,739,270. In August 2021, in response to a Motion to Stay filed by the Company, the court stayed the Consolidated Lawsuit pending the outcome of the IPR proceedings. In January 2022, the PTAB of the USPTO issued a decision instituting IPR on U.S. Patent No. 10,087,408 and a decision denying IPR on U.S. Patent No. 10,421,936. In February 2022, the PTAB issued a decision denying IPR on U.S. Patent No. 10,739,270. And in January 2023, the PTAB issued a decision upholding the validity of the challenged claims in U.S. Patent No. 10,087,408: the Company has requested a rehearing of the PTAB’s decision. The Consolidated Lawsuit remains stayed at this time, AbCellera has filed a motion - opposed by the Company - to lift the stay. AbCellera’s motion to lift the stay is fully briefed and awaiting a decision from the court. The Company believes that the patent assertions by AbCellera and UBC are without merit and it intends to defend itself vigorously. The Company also intends to proceed with its claims and counterclaims against AbCellera and UBC. Outcomes in litigation can be uncertain and it is possible a court may disagree with the Company’s position. An adverse determination in these lawsuits could subject the Company to significant liabilities, require it to seek licenses from or pay royalties to AbCellera and/or UBC, or prevent it from manufacturing, selling or using certain of the Company’s products, any of which could have a material adverse effect on the Company’s business, financial condition, results of operations and prospects. Securities Class Action In December 2021, Victor J. Ng filed a securities class action complaint in the Northern District of California (“Securities Class Action”), which was amended on July 25, 2022. The Securities Class Action is on behalf of all persons who purchased or otherwise acquired: (a) Berkeley Lights common stock pursuant and/or traceable to certain July 2020 Initial Public Offering (“IPO”) offering documents and/or (b) securities of Berkeley Lights between July 17, 2020 and January 5, 2022, inclusive. The complaint alleges claims under §§10(b) and 20(a) of the Securities Exchange Act of 1934 (“Exchange Act”) and Rule 10b-5 promulgated thereunder as well as §§11, 12(a)(2) and 15 of the Securities Act of 1933. It names as defendants the Company, certain of the Company’s current and former senior executives and directors, the underwriter firms that sponsored the Company’s July 2020 IPO, and three firms that invested in the Company. The Company believes that the assertions in the Securities Class Action are without merit and intends to defend itself vigorously. The Company’s pending Motion to Dismiss is set for hearing on June 22, 2023. Outcomes in litigation can be uncertain and it is possible a court may disagree with the Company’s positions. An adverse determination in the Securities Class Action could subject the Company to significant liabilities, which could have a material adverse effect on the Company’s business, financial condition, results of operations and prospects. Derivative Action In March 2022, Trung Nguyen filed a shareholder derivative complaint on behalf of nominal defendant Berkeley Lights, Inc., alleging that certain of the Company’s current and former directors and certain of the Company’s current and former senior executives breached their fiduciary duties to the Company. The complaint also alleged that certain of the Company’s current and former directors and former senior executives used material, non-public information to improperly profit from the sale of Company stock, and that certain of the Company’s current and former senior executives owe the Company contribution for violations of Sections 10(b) and 21D of the Exchange Act. The Company is not currently involved in any other claims or legal actions, nor is management aware of any potential claims or legal actions, for which the ultimate disposition could have a material adverse effect on the Company’s financial position, results of operations, or liquidity. No provision has been made for litigation because the Company believes that it is not probable that a liability has been incurred as of March 31, 2023. Purchase commitments The Company has entered into various purchase agreements, including inventory-related agreements with its contract manufacturers. Once these orders are placed, they are generally cancelable by providing notice prior to the expected ship date, however such cancellations could result in the Company incurring certain charges depending on the timing. The Company had non-cancellable purchase obligations to contract manufacturers and other suppliers of $29.7 million at March 31, 2023. Product Warranty The Company generally provides a one year assurance-type warranty on its platforms and chip consumables. The table below represents the activity in the product warranty accrual included in accrued expenses and other current liabilities on the condensed consolidated balance sheets (in thousands): Three months ended March 31, 2023 2022 Balance, beginning of period $ 749 $ 1,085 Warranty accrual assumed in IsoPlexis Merger 128 — Adjustments to existing warranties (111) (245) Provision for new warranties 133 163 Settlement of pre-existing warranties (111) (89) Balance, end of period $ 788 $ 914

Net Loss Attributable to Common

Net Loss Attributable to Common Stockholders Per Share	3 Months Ended
	Mar. 31, 2023
Earnings Per Share [Abstract]
Net Loss Attributable to Common Stockholders Per Share	Net Loss Attributable to Common Stockholders Per Share Potentially issuable shares of common stock include shares issuable upon the exercise of outstanding employee stock option awards and unvested restricted stock units. The following table sets forth the computation of basic and diluted earnings per common share (in thousands, except share and per share data): Three months ended March 31, 2023 2022 Numerator Net loss attributable to common stockholders, basic and diluted $ (23,419) $ (21,426) Denominator Weighted-average shares used to compute net income per share, basic and diluted 75,759,771 67,697,488 Net loss per share Net loss per share attributable to common stockholders, basic and diluted $ (0.31) $ (0.32) Since the Company was in a loss position for all periods presented, basic net loss per share attributable to common stockholders is the same as diluted net loss per share attributable to common stockholders, as the inclusion of all potential shares of common stock outstanding would have been anti-dilutive. The following shares of common stock equivalents were excluded from the calculation of diluted net loss per share attributable to common stockholders for the periods presented as they had an anti-dilutive effect: March 31, 2023 2022 Warrants to purchase common stock 496,560 — Options to purchase common stock 7,685,997 7,020,591 Restricted stock awards 290,846 — Restricted stock units 5,517,488 3,629,310 Total 13,990,891 10,649,901

Segments

Segments	3 Months Ended
	Mar. 31, 2023
Segment Reporting [Abstract]
Segments	Segments Operating segments are defined as components of an enterprise about which separate financial information is available that is evaluated regularly by the chief operating decision maker, or decision-making group, in deciding how to allocate resources and in assessing performance. The Company’s chief operating decision maker is its Chief Executive Officer. The Company has one business activity and there are no segment managers who are held accountable for operations. Accordingly, the Company has one operating segment. The IsoPlexis Merger on March 21, 2023 did not change the Company’s assessment about operating segments. The Company’s principal operations and decision-making functions are located in the United States. The following table provides the Company’s revenues by geographical market based on the location where the services were provided or to which product was shipped (in thousands): Three months ended March 31, 2023 2022 North America $ 14,055 $ 13,715 Asia Pacific (1) 3,147 5,035 Europe 1,314 1,456 $ 18,516 $ 20,206 (1) Asia Pacific includes Australia. As of March 31, 2023 and December 31, 2022, substantially all of the Company’s long-lived assets were located in the United States .

Subsequent Events

Subsequent Events	3 Months Ended
	Mar. 31, 2023
Subsequent Events [Abstract]
Subsequent Events	Subsequent EventsIn April 2023, Phenomenex, Inc. (“Phenomenex”) filed a complaint against the Company in the U.S. District Court for the Central District of California, alleging trademark infringement and unfair competition in relation to the Company’s name and seeking injunctive relief and damages. As of the filing date for this Quarterly Report on Form 10-Q, the Company has not been served with the complaint from Phenomenex. The Company believes that Phenomenex’s complaint is without merit and intends to vigorously defend itself. Restructuring During the second quarter of 2023, the Company announced a reduction in force terminating approximately 12% of total full-time employees. The Company estimates it will incur severance and employee-related restructuring costs of approximately $0.8 million related to this activity, substantially all of which the Company expects to incur in the second quarter of 2023.

The Company and Basis of Pres_2

The Company and Basis of Presentation (Policies)	3 Months Ended
	Mar. 31, 2023
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Basis of Presentation	Basis of Presentation On December 21, 2022, Berkeley Lights, Inc. (“Berkeley Lights”) entered into an Agreement and Plan of Merger (“Merger Agreement”) with Iceland Merger Sub Inc., a wholly owned subsidiary of Berkeley Lights (“Merger Sub”) and IsoPlexis Corporation (“IsoPlexis”). Pursuant to the Merger Agreement on March 21, 2023 (“Acquisition Date”), Merger Sub was merged with IsoPlexis, with IsoPlexis surviving the merger as a wholly owned subsidiary of Berkeley Lights (“IsoPlexis Merger”). The newly combined company has been renamed PhenomeX. The historical financial statements of PhenomeX for periods prior to the IsoPlexis Merger are the historical financial statements of Berkeley Lights.
Cash, cash equivalents and restricted cash	Cash, cash equivalents and restricted cash The Company considers all highly liquid investments with a maturity of three months or less when purchased to be cash equivalents.
Accounts Receivables and Allowance for Credit Losses	Accounts Receivables and Allowance for Credit Losses Trade accounts receivable are recorded at the invoiced amount as a result of the transaction with customers. The Company maintains allowances for credit losses for uncollectible accounts receivable. The Company estimates anticipated losses from doubtful accounts based on days past due, historical collection history, and other factors. Write-offs are recorded at the time all collection efforts have been exhausted. The Company reviews its allowance for doubtful accounts on a quarterly basis.
Inventory	Inventory Inventories are recorded at the lower of cost, determined on a first-in, first-out basis, or net realizable value. Inventory that is obsolete or in excess of forecasted usage is written down to its estimated net realizable value based on assumptions about future demand and market conditions. Inventory write-downs are charged to cost of goods sold and establish a new cost basis for the inventory. Costs included in inventories are raw materials, labor, supplies, allocable depreciation of manufacturing facilities, equipment and overhead.
Stock-based compensation	Stock-based compensation The Company maintains the 2020 Incentive Award Plan (“2020 Plan”), an incentive compensation plan under which stock options, restricted stock units (“RSUs”) and restricted stock awards (“RSAs”) are granted to employees, non-employee consultants and directors. Stock-based compensation expense is calculated based on the grant date fair value of the award. The Company determines the fair value of RSUs and RSAs based on the closing price of the Company’s common stock as reported by Nasdaq on the date of the grant. The Company estimates the fair value of the majority of stock option awards on the grant date using the Black-Scholes option-pricing model. For option awards that include a goal tied to the Company share price (i.e. a market condition) the Company uses a Monte Carlo simulation to estimate the fair value. The fair value of stock options, RSUs and RSAs with only a service condition is recognized as compensation expense on a straight-line basis over the requisite service period in which the awards are expected to vest and forfeitures are recognized as they occur. Stock options and RSUs that include a service condition and a performance condition are considered expected to vest when the performance condition is probable of being met. Compensation expense associated with performance awards that are determined to be probable of achievement is recognized over the requisite service period on a tranche-by-tranche basis. For performance stock options and RSUs not initially assessed as probable of achievement, the Company records a cumulative adjustment to compensation expense in the period the Company changes its determination that a performance condition becomes probable of being achieved. The Company ceases recognition of compensation expense in any periods where the Company determines the attainment of a performance condition is no longer probable. If the performance goals are determined to be improbable, any previously recognized compensation expense is reversed. The fair value of stock options with a market condition is recognized over the requisite service period for each tranche of the award and is recognized regardless of whether (or to what extent) the market condition is ultimately achieved.
Business Combinations	Business Combinations We account for business combinations using the acquisition method of accounting, which generally requires that assets acquired and liabilities assumed be recorded at their fair values as of the Acquisition Date on our Condensed Consolidated Balance Sheets. Any excess of consideration over the fair value of net assets acquired is recorded as goodwill. The determination of estimated fair value requires us to make significant estimates and assumptions. As a result, we may record adjustments to the fair values of assets acquired and liabilities assumed
Goodwill and Intangible Assets	Goodwill and Intangible Assets Goodwill represents the excess of the consideration transferred over the estimated fair value of assets acquired and liabilities assumed in a business combination. Intangible assets are measured at their respective fair values as of the Acquisition Date and may be subject to adjustment within the measurement period, which may be up to one year from the Acquisition Date. The Company does not amortize goodwill and intangible assets with indefinite useful lives. Goodwill and indefinite-lived intangible assets are tested for impairment annually, or more frequently if events or changes in circumstances indicate that it is more likely than not that the assets are impaired. Such triggering events potentially warranting an annual or interim goodwill impairment assessment include, among other factors, declines in historical or projected revenue, operating income or cash flows, and sustained decreases in the Company’s stock price or market capitalization. During the three months ended March 31, 2023, the Company experienced a decline in its market capitalization as a result of a sustained decrease in the Company’s stock price. Although the Company only recently acquired goodwill, as the Company operates as a single reporting unit, this sustained decrease was considered to represent a triggering event requiring management to perform a quantitative goodwill impairment test as of March 31, 2023. Refer to Note 8, Goodwill and Other Intangible Assets, for further information. Intangible assets with finite useful lives are amortized over their estimated useful lives, generally on a straight-line basis, and are reviewed for impairment when facts or circumstances indicate that the carrying value of these assets may not be recoverable.
Impairment of Long-Lived Assets	Impairment of Long-Lived Assets Long-lived assets, including property, plant and equipment and finite-lived intangible assets, are reviewed for impairment whenever facts or circumstances indicate that the carrying value of an asset may not be recoverable. Should there be an indication of impairment, we test for recoverability by comparing the estimated undiscounted future cash flows expected to result from the use of the asset to the carrying amount of the asset or asset group. If the asset or asset group is determined to be impaired, any excess of the carrying value of the asset or asset group over its estimated fair value is recognized as an impairment loss.
Foreign currency translation and transactions	Foreign currency translation and transactions The Company assesses the functional currency of each of its international subsidiaries. For subsidiaries where the functional currency is the U.S. dollar, gains or losses arising from currency exchange rate fluctuations on transactions denominated in a currency other than the U.S. dollar are included in other income (expense), net. For subsidiaries where the functional currency is the local currency, the translation of foreign currencies into U.S. dollars is performed for balance sheet accounts using exchange rates in effect at the balance sheet dates and revenue and expense accounts using the average exchange rate during each period. The gains and losses resulting from the translation are included in accumulated other comprehensive income in stockholders’ equity and are excluded from net income. The portions of intercompany accounts receivable and accounts payable that are intended for settlement are translated at exchange rates in effect at the balance sheet date.
Research and development state tax credits	Research and development state tax credits Research and development (“R&D”) tax credits exchanged for cash pursuant to the Connecticut R&D Tax Credit Exchange Program, which permits a qualified small business engaged in R&D activities within Connecticut to exchange its unused R&D tax credits for a cash amount equal to 65% of the value of exchanged credits, are
Warrants	Warrants On March 21, 2023 and in connection with the closing of the IsoPlexis Merger, PhenomeX, IsoPlexis and Perceptive Credit Holdings III, LP (“Perceptive”) executed a warrant certificate to purchase shares of PhenomeX stock (“Warrant Certificate”). The Company accounts for these common stock warrants as equity classified instruments in accordance with ASC 480, Distinguishing Liabilities from Equity.

Summary of Significant Accoun_2

Summary of Significant Accounting Policies (Tables)	3 Months Ended
	Mar. 31, 2023
Accounting Policies [Abstract]
Schedule of cash and cash equivalents and restricted cash	The following table provides a reconciliation of cash, cash equivalents and restricted cash included in our condensed consolidated balance sheets to the totals presented on the condensed consolidated statements of cash flows (in thousands): March 31, 2023 December 31, 2022 Cash $ 45,015 $ 63,596 Cash equivalents 6,591 22,926 Restricted cash 70,093 — Total cash, cash equivalents and restricted cash as presented on the condensed consolidated statements of cash flows $ 121,699 $ 86,522
Schedule of cash and cash equivalents and restricted cash	The following table provides a reconciliation of cash, cash equivalents and restricted cash included in our condensed consolidated balance sheets to the totals presented on the condensed consolidated statements of cash flows (in thousands): March 31, 2023 December 31, 2022 Cash $ 45,015 $ 63,596 Cash equivalents 6,591 22,926 Restricted cash 70,093 — Total cash, cash equivalents and restricted cash as presented on the condensed consolidated statements of cash flows $ 121,699 $ 86,522

Marketable Securities (Tables)

Marketable Securities (Tables)	3 Months Ended
	Mar. 31, 2023
Investments, Debt and Equity Securities [Abstract]
Schedule of unrealized gains and losses related to our available-for-sale marketable securities	The following tables summarize the amortized costs and carrying value of the Company’s available-for-sale securities, by balance sheet classification and major security type, as of March 31, 2023 and December 31, 2022 (in thousands): Marketable Securities reported as Cash Equivalents March 31, 2023 Amortized Cost Unrealized Gains Unrealized Losses Fair Value Money market funds $ 6,591 $ — $ — $ 6,591 Total $ 6,591 $ — $ — $ 6,591 December 31, 2022 Amortized Cost Unrealized Gains Unrealized Losses Fair Value Money market funds $ 2,354 $ — $ — $ 2,354 Commercial paper 16,606 — (4) 16,602 U.S. agency securities 3,969 1 — 3,970 U.S. government securities — — — — Total $ 22,929 $ 1 $ (4) $ 22,926 Marketable Securities reported as Short-term Marketable Securities As of March 31, 2023, the Company did not hold any short-term marketable securities. Realized gains/losses from the sale of short-term marketable securities during the three months ended March 31, 2023 were immaterial. Short-term marketable securities at December 31, 2022 were as follows (in thousands): December 31, 2022 Amortized Cost Unrealized Gains Unrealized Losses Fair Value Commercial paper $ 22,158 $ 1 $ (11) $ 22,148 U.S. agency securities 4,941 1 — 4,942 U.S. government securities 19,159 5 (2) 19,162 Total $ 46,258 $ 7 $ (13) $ 46,252

Business Combinations (Tables)

Business Combinations (Tables)	3 Months Ended
	Mar. 31, 2023
Business Combination and Asset Acquisition [Abstract]
Schedule of fair value of consideration transferred	The Acquisition Date fair value of consideration transferred in the IsoPlexis Merger totaled $84.9 million, summarized as follows (in thousands): Fair value of PhenomeX common stock issued to IsoPlexis stockholders (1) $ 31,930 Repayment of IsoPlexis debt (2) 52,482 Fair value of vested IsoPlexis options attributable to pre-merger service (3) 306 Fair value of IsoPlexis warrant at Acquisition Date (4) 170 Total purchase consideration $ 84,888 (1) Represents the fair value of PhenomeX common stock issued to IsoPlexis stockholders pursuant to the Merger Agreement. The fair value is based on 24,945,611 shares of PhenomeX common stock at $1.28 per share on March 21, 2023 issued to IsoPlexis stockholders. IsoPlexis stockholders received 0.612 shares of PhenomeX stock for each IsoPlexis share they held. (2) Represents $50 million in principal repayment to retire debt of IsoPlexis, as required by change in control provisions of the debt, as well as prepayment penalties and accrued interest. (3) Represents the fair value at March 21, 2023 of IsoPlexis options assumed by PhenomeX attributable to pre-combination service (see Note 13 for additional information). (4) Represents the fair value of the IsoPlexis warrant assumed by PhemoneX at March 21, 2023 (see Note 13 for additional information).
Schedule of fair value of assets acquired and liabilities assumed	The following table summarizes the preliminary fair values for each major class of assets acquired and liabilities assumed at the Acquisition Date (in thousands). The Company used third party valuation professionals to aid in the determination of the estimated fair value of certain assets acquired and liabilities assumed. The Company is in the process of finalizing the purchase price allocation associated with this transaction. As such, the preliminary purchase allocation set forth below is subject to revision as additional information is obtained and the valuation process is completed. Cash and cash equivalents $ 12,197 Accounts receivable 3,075 Inventories 27,287 Prepaid expenses and other current assets 4,190 Property and equipment, net 11,206 Intangible assets 22,900 Goodwill 12,246 Operating lease right-of-use assets 4,975 Other assets 526 Total assets acquired 98,602 Accounts payable 2,367 Accrued expenses and other current liabilities 4,912 Deferred revenue 1,399 Operating lease obligations 5,036 Total liabilities assumed 13,714 Total consideration transferred $ 84,888
Schedule of pro forma information	The following unaudited pro forma financial information gives effect to the IsoPlexis Merger as if it had been completed on January 1, 2022. The unaudited pro forma information was prepared in accordance with the requirements of ASC 805, which is a different basis than pro forma information prepared under Article 11 of Regulation S-X (“Article 11”). As such, they are not directly comparable with historical results for stand-alone Berkeley Lights prior to March 21, 2023 or our previously provided pro forma financials prepared in accordance with Article 11. The pro forma adjustments are based on historical reported transactions by the respective companies and do not include any anticipated synergies or other expected benefits of the acquisition. (in thousands) Three months ended March 31, 2023 Three months ended March 31, 2022 Total revenue $ 20,170 $ 25,117 Net loss $ (66,463) $ (50,419)

Revenue From Contracts With C_2

Revenue From Contracts With Customers (Tables)	3 Months Ended
	Mar. 31, 2023
Revenue from Contract with Customer [Abstract]
Schedule of disaggregation of revenue	The following tables provide an overview of the Company’s revenue streams and how the Company reports revenue in its consolidated statements of operations: Income Statement Classification Product or Service sold Revenue Stream Product revenue Sale of advanced automation systems (Beacon and Lightning systems, Culture Station) Platform Software and workflow licenses Platform Fixed term sales-type lease arrangements with qualified customers Platform Quarterly workflow subscriptions, annual or multi-year subscriptions arrangements (e.g. TechAccess) Recurring Consumables and reagent kits (e.g. OptoSelect chips) Recurring Service and other revenue Strategic partnerships, joint development and collaboration agreements where we provide services for development of new workflows, cells or organism types Partnership, License and Other Application support, installation and training Platform Fixed fee extended warranty and service programs Recurring IP license revenue Partnership, License and Other (1) (1) License revenue relates to certain intellectual property acquired in the IsoPlexis Merger and subsequently licensed to a third party. License revenue related to our platforms (e.g. workflow licenses) is reported as Platform product revenue. The following tables provide information by revenue stream for the periods presented: Three Months Ended March 31, 2023 (in thousands) Product Service and other Total Platform $ 5,773 $ 330 $ 6,103 Recurring 2,605 2,558 5,163 Partnership, License and Other (1) — 7,250 7,250 Total revenue $ 8,378 $ 10,138 $ 18,516 (1) During the three months ended March 31, 2023, the Company signed an agreement to license, on an exclusive and perpetual basis, certain intellectual property acquired in the IsoPlexis Merger for $7.3 million (“License Agreement”). As the $7.3 million represented a non-refundable fee and the license was transferred to the customer during the quarter, the $7.3 million was recognized as revenue during the quarter, which represents all the Partnership, License, and Other revenue during the quarter. Three Months Ended March 31, 2022 (in thousands) Product Service and other Total Platform $ 6,747 $ 657 $ 7,404 Recurring 3,027 2,416 5,443 Partnership, License and Other — 7,359 7,359 Total revenue $ 9,774 $ 10,432 $ 20,206
Schedule of receivables, contract assets and deferred revenue from contracts with customers	The following table provides information about receivables, contract assets and deferred revenue from contracts with customers (in thousands): March 31, December 31, Trade accounts receivable, net $ 25,119 $ 18,534 Contract assets, which are included in “Prepaid expenses and other current assets” $ 367 $ 1,283 Contract assets, long-term, which are included in “Other assets” $ 514 $ 549 Deferred revenue (current) $ 10,746 $ 9,092 Deferred revenue (non-current) $ 1,259 $ 963
Schedule of sales-type lease maturity	The following table presents the future maturity of the Company’s fixed-term customer leases and reconciles the undiscounted cash flows from the amounts due from customers under such arrangements as of March 31, 2023 (in thousands): Year ending December 31, Sales-Type Remainder of 2023 (1) $ 334 2024 445 2025 408 2026 — Total undiscounted cash flows 1,187 Less: unearned income (171) Total amounts due from customers (2) $ 1,016 (1) During the three months ended March 31, 2023, the Company impaired the net investment of a sales type lease with a customer. The write down of the respective contract asset of $0.8 million, net of the return of the underlying asset, was recorded as an impairment charge of $0.6 million within selling, general and administrative expense in the Company’s condensed consolidated statement of operations and the resulting return of the underlying asset was recorded as an addition to fixed assets in the Company’s condensed consolidated balance sheet.

Balance Sheet Accounts (Tables)

Balance Sheet Accounts (Tables)	3 Months Ended
	Mar. 31, 2023
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Schedule of trade accounts receivable, net	Trade accounts receivable, net consists of the following (in thousands): March 31, December 31, Trade accounts receivable $ 26,013 $ 18,534 Allowance for doubtful accounts (894) — Total $ 25,119 $ 18,534
Schedule of changes in the allowance for doubtful accounts	Changes in the allowance for doubtful accounts were as follows (in thousands): Three months ended March 31, 2023 Allowance for doubtful accounts, beginning of year $ — Allowance assumed in IsoPlexis Merger (721) Write-offs of uncollectible accounts — Provision for doubtful accounts (173) Allowance for doubtful accounts, end of period $ (894)
Schedule of inventory	The following table shows the components of inventory (in thousands): March 31, December 31, Raw materials $ 32,816 $ 11,946 Work in progress 1,106 — Finished goods 11,617 6,915 Total $ 45,539 $ 18,861
Schedule of prepaid expenses and other current assets	The following table shows the components of prepaid expenses and other current assets (in thousands): March 31, December 31, Contract asset $ 367 $ 1,283 Vendor deposits 421 126 Deferred costs 365 472 Prepaid insurance 3,534 2,025 Other (1) 4,691 2,877 Total $ 9,378 $ 6,783 (1) Other includes primarily prepaid rent expenses, software licenses and prepaid VAT.
Schedule of accrued expenses and other current liabilities	The following table shows the components of accrued expenses and other current liabilities (in thousands): March 31, December 31, Accrued payroll and employee related expenses $ 6,611 $ 7,410 Lease liability – short-term 4,958 3,291 Accrued product warranty 788 749 Accrued legal expenses 5,499 8,271 Other (1) 1,789 1,619 Total $ 19,645 $ 21,340 (1) Other includes accrued income taxes, sales taxes, accrued royalties and other miscellaneous accruals.

Goodwill and Other Intangible_2

Goodwill and Other Intangible Assets (Tables)	3 Months Ended
	Mar. 31, 2023
Goodwill and Intangible Assets Disclosure [Abstract]
Schedule of intangible assets	These intangible assets are also included in the table below. March 31, 2023 (in thousands): Remaining Useful Life (Years) Gross Accumulated Amortization Net Customer relationships 8 $ 7,700 $ (5) $ 7,695 Trade names 10 3,500 (11) 3,489 Patented technology 14 11,911 (23) 11,888 Total intangible assets $ 23,111 $ (39) $ 23,072
Schedule of estimated annual amortization of intangible assets	The estimated annual amortization of intangible assets for the remainder of 2023 and the next four years is presented in the table below (in thousands). Actual amortization expense to be reported in future periods could differ from these estimates as a result of the finalization of the preliminary purchase price allocation of the IsoPlexis Merger, divestitures and other factors. March 31, 2023 Year Ending December 31: Remainder of 2023 $ 1,689 2024 $ 2,163 2025 $ 2,163 2026 $ 2,163 2027 $ 2,163

Fair Value of Financial Instr_2

Fair Value of Financial Instruments (Tables)	3 Months Ended
	Mar. 31, 2023
Fair Value Disclosures [Abstract]
Schedule of financial assets measured at fair value	At March 31, 2023 and December 31, 2022, the fair value measurements of the Company’s assets measured on a recurring basis were as follows: (in thousands): March 31, Quoted Prices Significant Significant Cash equivalents: Money market funds $ 6,591 $ 6,591 $ — $ — Total assets measured at fair value $ 6,591 $ 6,591 $ — $ — December 31, Quoted Prices Significant Significant Cash equivalents: Money market funds $ 2,354 $ 2,354 $ — $ — Commercial paper 16,602 — 16,602 — U.S. agency securities 3,970 — 3,970 — Total cash equivalents 22,926 2,354 20,572 — Debt securities, available for sale: Commercial paper 22,148 — 22,148 — U.S. agency securities 4,942 — 4,942 — U.S. government securities 19,162 — 19,162 — Total debt securities, available for sale 46,252 — 46,252 — Total assets measured at fair value $ 69,178 $ 2,354 $ 66,824 $ —
Schedule of financial instruments not measured at fair value	The carrying values and fair values of the Company’s financial instruments not measured at fair value were as follows (in thousands): March 31, 2023 December 31, 2022 Carrying Fair Value Carrying Fair Value Long-term debt, including current maturities $ 68,886 $ 70,000 $ 19,826 $ 17,443

Property and Equipment, net (Ta

Property and Equipment, net (Tables)	3 Months Ended
	Mar. 31, 2023
Property, Plant and Equipment [Abstract]
Schedule of property and equipment	Property and equipment, net comprised the following (in thousands): March 31, December 31, Equipment, tooling and molds $ 47,577 $ 36,152 Computer software and equipment 8,037 2,667 Furniture, fixtures and other 2,600 2,007 Leasehold improvements 12,509 10,836 Construction in process 1,370 1,409 Total property and equipment 72,093 53,071 Less: Accumulated depreciation (38,251) (29,224) Property and equipment, net (1) $ 33,842 $ 23,847 (1) Property and equipment, net at each of March 31, 2023 and December 31, 2022 includes $0.1 million of assets held for sale.

Leases (Table)

Leases (Table)	3 Months Ended
	Mar. 31, 2023
Leases [Abstract]
Schedule of operating lease liabilities maturity	Future payments associated with the Company’s operating lease liabilities as of March 31, 2023 are as follows (in thousands): Operating leases Undiscounted lease payments for the year ending December 31, Remainder of 2023 $ 4,691 2024 6,297 2025 5,952 2026 5,398 2027 4,759 Thereafter 7,464 Total undiscounted lease payments 34,561 Less: implied interest (4,304) Less: tenant improvement allowances receivable (65) Present value of operating lease payments 30,192 Less: current portion (1) (4,958) Total long-term operating lease liabilities $ 25,234 (1) Included in the balance sheet caption “Accrued expenses and other current liabilities.”
Schedule of supplemental cash flow information related to operating leases	The following information represents supplemental disclosure for the statement of cash flows related to operating leases (in thousands): Three months ended March 31, 2023 Three months ended March 31, 2022 Right-of-use assets obtained for new operating lease liabilities $ — $ — Right-of-use lease assets assumed in IsoPlexis Merger $ 4,975 $ — Cash paid for amounts included in the measurement of lease liabilities $ 989 $ 1,098
Schedule of additional information related to operating leases	The following summarizes additional information related to operating leases: March 31, 2023 December 31, 2022 Weighted-average remaining lease term (years) 5.71 6.48 Weighted-average discount rate 4.73 % 4.66 %

Long-Term Debt (Tables)

Long-Term Debt (Tables)	3 Months Ended
	Mar. 31, 2023
Debt Disclosure [Abstract]
Schedule of payments due on notes payable	The following is a schedule of payments due on notes payable as of March 31, 2023 (in thousands): March 31, Year Ending December 31: Remainder of 2023 $ 4,545 2024 6,049 2025 13,680 2026 15,437 2027 14,532 2028 41,990 Total payments due 96,233 Less: Interest payments, loan discounts and financing costs (27,347) Current portion, less loan discounts and financing costs — Notes payable, net of current portion $ 68,886

Equity and Stock Compensation_2

Equity and Stock Compensation Plans (Tables)	3 Months Ended
	Mar. 31, 2023
Share-Based Payment Arrangement [Abstract]
Schedule of stock-based compensation	Stock-based compensation related to the Company’s stock-based awards was recorded as an expense and allocated as follows (in thousands): Three months ended March 31, 2023 2022 Cost of sales $ 16 $ 51 Research and development 548 1,581 Selling, general and administrative 3,824 3,761 Total stock-based compensation $ 4,388 $ 5,393

Restructuring (Tables)

Restructuring (Tables)	3 Months Ended
	Mar. 31, 2023
Restructuring and Related Activities [Abstract]
Schedule of Changes in Restructuring Liability	Changes in the Company’s restructuring liability are set forth in the table below (in thousands): Employee severance and termination benefits Non labor restructuring Total Accrual at January 1, 2023 $ 130 $ 107 $ 237 Restructuring liability assumed in IsoPlexis Merger 834 — 834 Restructuring charges 1,290 — 1,290 Cash payments (1,010) (107) (1,117) Non-cash settlements — — — Accrual at March 31, 2023 $ 1,244 $ — $ 1,244

Statements of Cash Flows (Table

Statements of Cash Flows (Tables)	3 Months Ended
	Mar. 31, 2023
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Schedule of cash flow, supplemental disclosures	The supplemental cash flow information consists of the following (in thousands): Three months ended March 31, 2023 2022 Cash paid for interest $ 439 $ 137 Cash paid for income taxes $ 19 $ — Non-cash investing and financing activities Non-cash consideration for the acquisition of IsoPlexis $ 32,406 $ — Property and equipment transferred to inventory $ 352 $ — Customer return of Beacon transferred to property and equipment (1) $ 201 $ — Change in accounts payable and accrued liabilities related to purchases of property and equipment $ 684 $ 482 (1) Refer to Note 6 under “Sales-type Lease Arrangements” for further information.

Commitment and Contingencies (T

Commitment and Contingencies (Tables)	3 Months Ended
	Mar. 31, 2023
Commitments and Contingencies Disclosure [Abstract]
Schedule of product warranty liability	The table below represents the activity in the product warranty accrual included in accrued expenses and other current liabilities on the condensed consolidated balance sheets (in thousands): Three months ended March 31, 2023 2022 Balance, beginning of period $ 749 $ 1,085 Warranty accrual assumed in IsoPlexis Merger 128 — Adjustments to existing warranties (111) (245) Provision for new warranties 133 163 Settlement of pre-existing warranties (111) (89) Balance, end of period $ 788 $ 914

Net Loss Attributable to Comm_2

Net Loss Attributable to Common Stockholders Per Share (Tables)	3 Months Ended
	Mar. 31, 2023
Earnings Per Share [Abstract]
Schedule of basic and diluted net loss per common share	The following table sets forth the computation of basic and diluted earnings per common share (in thousands, except share and per share data): Three months ended March 31, 2023 2022 Numerator Net loss attributable to common stockholders, basic and diluted $ (23,419) $ (21,426) Denominator Weighted-average shares used to compute net income per share, basic and diluted 75,759,771 67,697,488 Net loss per share Net loss per share attributable to common stockholders, basic and diluted $ (0.31) $ (0.32)
Schedule of antidilutive securities excluded from computation of earnings per share	The following shares of common stock equivalents were excluded from the calculation of diluted net loss per share attributable to common stockholders for the periods presented as they had an anti-dilutive effect: March 31, 2023 2022 Warrants to purchase common stock 496,560 — Options to purchase common stock 7,685,997 7,020,591 Restricted stock awards 290,846 — Restricted stock units 5,517,488 3,629,310 Total 13,990,891 10,649,901

Segments (Tables)

Segments (Tables)	3 Months Ended
	Mar. 31, 2023
Segment Reporting [Abstract]
Summary of revenue by geographic areas	The following table provides the Company’s revenues by geographical market based on the location where the services were provided or to which product was shipped (in thousands): Three months ended March 31, 2023 2022 North America $ 14,055 $ 13,715 Asia Pacific (1) 3,147 5,035 Europe 1,314 1,456 $ 18,516 $ 20,206 (1) Asia Pacific includes Australia.

The Company and Basis of Pres_3

The Company and Basis of Presentation (Details) - USD ($)		3 Months Ended
	Mar. 21, 2023	Mar. 31, 2023	Mar. 31, 2022	Mar. 20, 2023	Dec. 31, 2022	Jun. 30, 2021	May 23, 2018
Organization, Consolidation and Presentation of Financial Statement [Line Items]
Net loss		$ (23,419,000)	$ (21,426,000)
Accumulated deficit		(385,067,000)			$ (361,648,000)
Cash, cash equivalents, and marketable securities		$ 51,600,000
EWB Term Loan | Notes Payable
Organization, Consolidation and Presentation of Financial Statement [Line Items]
Maximum borrowing capacity	$ 70,000,000			$ 20,000,000		$ 20,000,000	$ 20,000,000
Debt instrument, covenant description, cash	70,000,000
Perceptive Credit Agreement | Line of Credit
Organization, Consolidation and Presentation of Financial Statement [Line Items]
Repayment of acquired debt	$ 52,500,000

Summary of Significant Accoun_3

Summary of Significant Accounting Policies - Narrative (Details) - USD ($) $ in Thousands	Mar. 31, 2023	Dec. 31, 2022
Restricted Cash and Cash Equivalents Items [Line Items]
Restricted cash	$ 70,093	$ 0
Letter of Credit
Restricted Cash and Cash Equivalents Items [Line Items]
Restricted cash	100
EWB Term Loan
Restricted Cash and Cash Equivalents Items [Line Items]
Restricted cash	$ 70,000

Summary of Significant Accoun_4

Summary of Significant Accounting Policies - Cash, Cash Equivalents and Restricted Cash (Details) - USD ($) $ in Thousands	Mar. 31, 2023	Dec. 31, 2022	Mar. 31, 2022	Dec. 31, 2021
Accounting Policies [Abstract]
Cash	$ 45,015	$ 63,596
Cash equivalents	6,591	22,926
Restricted cash	70,093	0
Total cash, cash equivalents and restricted cash as presented on the condensed consolidated statements of cash flows	$ 121,699	$ 86,522	$ 164,944	$ 178,366

Summary of Significant Accoun_5

Summary of Significant Accounting Policies - Research and development state tax credits (Details) $ in Millions	Mar. 31, 2023 USD ($)
Research Tax Credit Carryforward
Tax Credit Carryforward [Line Items]
R&D tax credits receivable	$ 0.2

Marketable Securities - Unreali

Marketable Securities - Unrealized Gains and Losses Related to our Available-for-Sale Marketable Securities (Details) - USD ($) $ in Thousands	Mar. 31, 2023	Dec. 31, 2022
Cash and Cash Equivalents [Abstract]
Amortized Cost	$ 6,591	$ 22,929
Unrealized Gains	0	1
Unrealized Losses	0	(4)
Fair Value	6,591	22,926
Debt Securities, Available-for-Sale [Abstract]
Amortized Cost		46,258
Unrealized Gains		7
Unrealized Losses		(13)
Fair Value		46,252
Commercial paper
Debt Securities, Available-for-Sale [Abstract]
Amortized Cost		22,158
Unrealized Gains		1
Unrealized Losses		(11)
Fair Value		22,148
U.S. agency securities
Debt Securities, Available-for-Sale [Abstract]
Amortized Cost		4,941
Unrealized Gains		1
Unrealized Losses		0
Fair Value		4,942
U.S. government securities
Debt Securities, Available-for-Sale [Abstract]
Amortized Cost		19,159
Unrealized Gains		5
Unrealized Losses		(2)
Fair Value		19,162
Money market funds
Cash and Cash Equivalents [Abstract]
Amortized Cost	6,591	2,354
Unrealized Gains	0	0
Unrealized Losses	0	0
Fair Value	$ 6,591	2,354
Commercial paper
Cash and Cash Equivalents [Abstract]
Amortized Cost		16,606
Unrealized Gains		0
Unrealized Losses		(4)
Fair Value		16,602
U.S. agency securities
Cash and Cash Equivalents [Abstract]
Amortized Cost		3,969
Unrealized Gains		1
Unrealized Losses		0
Fair Value		3,970
U.S. government securities
Cash and Cash Equivalents [Abstract]
Amortized Cost		0
Unrealized Gains		0
Unrealized Losses		0
Fair Value		$ 0

Significant Risks and Uncerta_2

Significant Risks and Uncertainties Including Business and Credit Concentrations (Details) - USD ($) $ in Thousands	3 Months Ended		12 Months Ended
	Mar. 31, 2023	Mar. 31, 2022	Dec. 31, 2022
Concentration Risk [Line Items]
Allowance for doubtful accounts	$ 894		$ 0
Revenue | Customer | Customer One
Concentration Risk [Line Items]
Concentration risk percentage	39%	18%
Revenue | Customer | Customer Two
Concentration Risk [Line Items]
Concentration risk percentage	10%	13%
Revenue | Customer | Customer Three
Concentration Risk [Line Items]
Concentration risk percentage	10%	10%
Accounts Receivable | Customer | Customer One
Concentration Risk [Line Items]
Concentration risk percentage	25%		24%
Accounts Receivable | Customer | Customer Two
Concentration Risk [Line Items]
Concentration risk percentage	14%		11%
Accounts Receivable | Customer | Customer Three
Concentration Risk [Line Items]
Concentration risk percentage	12%

Business Combinations - Narrati

Business Combinations - Narrative (Details)		3 Months Ended
	Mar. 21, 2023 USD ($)	Mar. 31, 2023 USD ($)	Dec. 31, 2022 USD ($)	Mar. 31, 2022 USD ($)
Business Acquisition [Line Items]
Fair value of accounts receivable acquired	$ 3,100,000
Allowance for credit losses	700,000
Inventories	27,300,000
Step up form book value of inventory acquired	$ 4,900,000
Inventory		$ 45,539,000	$ 18,861,000
Incurred transaction costs		13,700,000
Total revenue		18,516,000		$ 20,206,000
Service and other revenue
Business Acquisition [Line Items]
Total revenue		10,138,000		10,432,000
Partnership, License and Other (1)
Business Acquisition [Line Items]
Total revenue		7,250,000		7,359,000
Partnership, License and Other (1) | Service and other revenue
Business Acquisition [Line Items]
Total revenue		7,250,000		$ 7,359,000
Acquisition-related Costs
Business Acquisition [Line Items]
Incurred transaction costs		4,400,000
IsoPlexis
Business Acquisition [Line Items]
Shares holding ratio	0.612
Inventories	$ 27,287,000
Inventory	22,400,000
Inventory valuation reserves	15,400,000
Goodwill with a provisional assigned value	12,200,000
Goodwill, expected tax deductible amount	$ 0
Recognized transaction costs		3,500,000	$ 2,800,000
Revenues		1,000,000
Operating loss		1,100,000
IsoPlexis | Partnership, License and Other (1) | Service and other revenue
Business Acquisition [Line Items]
Total revenue		$ 7,300,000
IsoPlexis | EWB Term Loan | Notes Payable
Business Acquisition [Line Items]
Interest rate	8.50%
IsoPlexis | Minimum
Business Acquisition [Line Items]
Weighted average useful life	8 years
IsoPlexis | Maximum
Business Acquisition [Line Items]
Weighted average useful life	14 years
IsoPlexis | Patented technology
Business Acquisition [Line Items]
Intangible assets	$ 11,700,000
IsoPlexis | Customer Relationships
Business Acquisition [Line Items]
Intangible assets	7,700,000
IsoPlexis | Trade Names and Trademarks
Business Acquisition [Line Items]
Intangible assets	$ 3,500,000

Business Combinations - Schedul

Business Combinations - Schedule of Acquired Assets and Liabilities (Details) $ / shares in Units, $ in Thousands	Mar. 21, 2023 USD ($) $ / shares shares	Mar. 31, 2023 USD ($)	Dec. 31, 2022 USD ($)
Fair value of assets acquired and liabilities assumed
Inventories	$ 27,300
Goodwill		$ 12,246	$ 0
IsoPlexis
Consideration Transferred
Fair value of PhenomeX common stock issued to IsoPlexis stockholders	31,930
Repayment of acquired debt	52,482
Fair value of vested IsoPlexis options attributable to pre-merger service	306
Fair value of IsoPlexis warrant at merger date	170
Total purchase consideration	$ 84,888
Fair value of common stock issued (in shares) | shares	24,945,611
Price per share of the common stock acquired (in dollars per share) | $ / shares	$ 1.28
Shares holding ratio	0.612
Principal repayment to retire debt	$ 50,000
Fair value of assets acquired and liabilities assumed
Cash and cash equivalents	12,197
Accounts receivable	3,075
Inventories	27,287
Prepaid expenses and other current assets	4,190
Property and equipment, net	11,206
Intangible assets	22,900
Goodwill	12,246
Operating lease right-of-use assets	4,975
Other assets	526
Total assets acquired	98,602
Accounts payable	2,367
Accrued expenses and other current liabilities	4,912
Deferred revenue	1,399
Operating lease obligations	5,036
Total liabilities assumed	13,714
Total consideration transferred	$ 84,888

Business Combinations - Sched_2

Business Combinations - Schedule of Pro forma Information (Details) - IsoPlexis - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2023	Mar. 31, 2022
Business Acquisition [Line Items]
Total revenue	$ 20,170	$ 25,117
Net loss	$ (66,463)	$ (50,419)

Revenue from Contracts with C_3

Revenue from Contracts with Customer (Narrative) (Details) - USD ($)	3 Months Ended
	Mar. 31, 2023	Mar. 31, 2022	Dec. 31, 2022
Revenue from Contract with Customer [Abstract]
Remaining performance obligation	$ 12,000,000
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items]
Contract liabilities	12,000,000		$ 10,100,000
Contract liability , revenue recognized	2,800,000
Lease income	$ 0	$ 0
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2023-04-01
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items]
Remaining performance obligation, percentage	50%
Remaining performance obligation, period	12 months

Revenue From Contracts With C_4

Revenue From Contracts With Customers (Schedule of Disaggregation of Revenue) (Details) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2023	Mar. 31, 2022
Disaggregation of Revenue [Line Items]
Total revenue	$ 18,516	$ 20,206
Platform
Disaggregation of Revenue [Line Items]
Total revenue	6,103	7,404
Recurring
Disaggregation of Revenue [Line Items]
Total revenue	5,163	5,443
Partnership, License and Other
Disaggregation of Revenue [Line Items]
Total revenue	7,250	7,359
Product
Disaggregation of Revenue [Line Items]
Total revenue	8,378	9,774
Product | Platform
Disaggregation of Revenue [Line Items]
Total revenue	5,773	6,747
Product | Recurring
Disaggregation of Revenue [Line Items]
Total revenue	2,605	3,027
Product | Partnership, License and Other
Disaggregation of Revenue [Line Items]
Total revenue	0	0
Service and other
Disaggregation of Revenue [Line Items]
Total revenue	10,138	10,432
Service and other | Platform
Disaggregation of Revenue [Line Items]
Total revenue	330	657
Service and other | Recurring
Disaggregation of Revenue [Line Items]
Total revenue	2,558	2,416
Service and other | Partnership, License and Other
Disaggregation of Revenue [Line Items]
Total revenue	7,250	$ 7,359
Service and other | Partnership, License and Other | IsoPlexis
Disaggregation of Revenue [Line Items]
Total revenue	$ 7,300

Revenue From Contracts With C_5

Revenue From Contracts With Customers (Schedule of Receivables, Contract Assets and Deferred Revenue) (Details) - USD ($) $ in Thousands	Mar. 31, 2023	Dec. 31, 2022
Revenue from Contract with Customer [Abstract]
Trade accounts receivable, net	$ 25,119	$ 18,534
Contract assets, which are included in “Prepaid expenses and other current assets”	367	1,283
Contract assets, long-term, which are included in “Other assets”	514	549
Deferred revenue (current)	10,746	9,092
Deferred revenue (non-current)	$ 1,259	$ 963

Revenue From Contracts With C_6

Revenue From Contracts With Customers (Sale-type Lease Arrangement) (Details) $ in Thousands	3 Months Ended
	Mar. 31, 2023 USD ($)
Lessor, Lease, Description [Line Items]
Remainder of 2023	$ 334
2024	445
2025	408
2026	0
Total undiscounted cash flows	1,187
Less: unearned income	(171)
Total amounts due from customers	1,016
Contract asset	800
Impairment charge	600
Accounts Receivable, after Allowance for Credit Loss, Current
Lessor, Lease, Description [Line Items]
Total amounts due from customers	$ 100

Balance Sheet Accounts - Trade

Balance Sheet Accounts - Trade Accounts Receivable, Net (Details) - USD ($) $ in Thousands	Mar. 31, 2023	Dec. 31, 2022
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Trade accounts receivable	$ 26,013	$ 18,534
Allowance for doubtful accounts	(894)	0
Trade accounts receivable, net	$ 25,119	$ 18,534

Balance Sheet Accounts - Change

Balance Sheet Accounts - Changes in Allowance for Doubtful Accounts (Details) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2023	Mar. 31, 2022
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Allowance for doubtful accounts, beginning of year	$ 0
Allowance assumed in IsoPlexis Merger	(721)
Write-offs of uncollectible accounts	0
Provision for doubtful accounts	(173)	$ 0
Allowance for doubtful accounts, end of period	$ (894)

Balance Sheet Accounts - Invent

Balance Sheet Accounts - Inventory (Details) - USD ($) $ in Thousands	Mar. 31, 2023	Dec. 31, 2022
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Raw materials	$ 32,816	$ 11,946
Work in progress	1,106	0
Finished goods	11,617	6,915
Total	$ 45,539	$ 18,861

Balance Sheet Accounts - Prepai

Balance Sheet Accounts - Prepaid Expenses and Other Current Assets (Details) - USD ($) $ in Thousands	Mar. 31, 2023	Dec. 31, 2022
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Contract asset	$ 367	$ 1,283
Vendor deposits	421	126
Deferred costs	365	472
Prepaid insurance	3,534	2,025
Other	4,691	2,877
Total	$ 9,378	$ 6,783

Balance Sheet Accounts - Accrue

Balance Sheet Accounts - Accrued Expenses and Other Current Liabilities (Details) - USD ($) $ in Thousands	Mar. 31, 2023	Dec. 31, 2022
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Accrued payroll and employee related expenses	$ 6,611	$ 7,410
Lease liability - short-term [Extensible Enumeration]	Total	Total
Lease liability – short-term	$ 4,958	$ 3,291
Accrued product warranty	788	749
Accrued legal expenses	5,499	8,271
Other	1,789	1,619
Total	$ 19,645	$ 21,340

Goodwill and Other Intangible_3

Goodwill and Other Intangible Assets - Narrative (Details) - USD ($) $ in Thousands		3 Months Ended
	Feb. 15, 2023	Mar. 31, 2023	Mar. 21, 2023	Dec. 31, 2022
Finite-Lived Intangible Assets [Line Items]
Goodwill		$ 12,246		$ 0
Amortization expense		$ (39)
Evorion Biotechnologies
Finite-Lived Intangible Assets [Line Items]
Total purchase price	$ 300
Evorion Biotechnologies | Patents and Technology
Finite-Lived Intangible Assets [Line Items]
Intangible assets acuired	$ 200
IsoPlexis
Finite-Lived Intangible Assets [Line Items]
Goodwill			$ 12,246

Goodwill and Other Intangible_4

Goodwill and Other Intangible Assets - Schedule of Intangible Assets (Details) $ in Thousands	3 Months Ended
	Mar. 31, 2023 USD ($)
Finite-Lived Intangible Assets [Line Items]
Intangible assets, gross	$ 23,111
Accumulated Amortization	(39)
Intangible assets, net	$ 23,072
Customer relationships
Finite-Lived Intangible Assets [Line Items]
Remaining Useful Life (Years)	8 years
Intangible assets, gross	$ 7,700
Accumulated Amortization	(5)
Intangible assets, net	$ 7,695
Trade names
Finite-Lived Intangible Assets [Line Items]
Remaining Useful Life (Years)	10 years
Intangible assets, gross	$ 3,500
Accumulated Amortization	(11)
Intangible assets, net	$ 3,489
Patented technology
Finite-Lived Intangible Assets [Line Items]
Remaining Useful Life (Years)	14 years
Intangible assets, gross	$ 11,911
Accumulated Amortization	(23)
Intangible assets, net	$ 11,888

Goodwill and Other Intangible_5

Goodwill and Other Intangible Assets - Schedule of Estimated Annual Amortization of Intangible Assets (Details) $ in Thousands	Mar. 31, 2023 USD ($)
Year Ending December 31:
Remainder of 2023	$ 1,689
2024	2,163
2025	2,163
2026	2,163
2027	$ 2,163

Fair Value of Financial Instr_3

Fair Value of Financial Instruments - Assets and Liabilities (Details) - USD ($) $ in Thousands	Mar. 31, 2023	Dec. 31, 2022
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Total debt securities, available for sale	$ 0	$ 46,252
Fair Value, Measurements, Recurring
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Total cash equivalents		22,926
Total debt securities, available for sale		46,252
Total assets measured at fair value	6,591	69,178
Commercial paper | Fair Value, Measurements, Recurring
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Total debt securities, available for sale		22,148
U.S. agency securities | Fair Value, Measurements, Recurring
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Total debt securities, available for sale		4,942
U.S. government securities | Fair Value, Measurements, Recurring
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Total debt securities, available for sale		19,162
Money market funds | Fair Value, Measurements, Recurring
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Total cash equivalents	6,591	2,354
Commercial paper | Fair Value, Measurements, Recurring
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Total cash equivalents		16,602
U.S. agency securities | Fair Value, Measurements, Recurring
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Total cash equivalents		3,970
Quoted Prices in Active Markets for Identical Assets (Level 1) | Fair Value, Measurements, Recurring
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Total cash equivalents		2,354
Total debt securities, available for sale		0
Total assets measured at fair value	6,591	2,354
Quoted Prices in Active Markets for Identical Assets (Level 1) | Commercial paper | Fair Value, Measurements, Recurring
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Total debt securities, available for sale		0
Quoted Prices in Active Markets for Identical Assets (Level 1) | U.S. agency securities | Fair Value, Measurements, Recurring
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Total debt securities, available for sale		0
Quoted Prices in Active Markets for Identical Assets (Level 1) | U.S. government securities | Fair Value, Measurements, Recurring
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Total debt securities, available for sale		0
Quoted Prices in Active Markets for Identical Assets (Level 1) | Money market funds | Fair Value, Measurements, Recurring
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Total cash equivalents	6,591	2,354
Quoted Prices in Active Markets for Identical Assets (Level 1) | Commercial paper | Fair Value, Measurements, Recurring
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Total cash equivalents		0
Quoted Prices in Active Markets for Identical Assets (Level 1) | U.S. agency securities | Fair Value, Measurements, Recurring
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Total cash equivalents		0
Significant Other Observable Inputs (Level 2) | Fair Value, Measurements, Recurring
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Total cash equivalents		20,572
Total debt securities, available for sale		46,252
Total assets measured at fair value	0	66,824
Significant Other Observable Inputs (Level 2) | Commercial paper | Fair Value, Measurements, Recurring
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Total debt securities, available for sale		22,148
Significant Other Observable Inputs (Level 2) | U.S. agency securities | Fair Value, Measurements, Recurring
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Total debt securities, available for sale		4,942
Significant Other Observable Inputs (Level 2) | U.S. government securities | Fair Value, Measurements, Recurring
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Total debt securities, available for sale		19,162
Significant Other Observable Inputs (Level 2) | Money market funds | Fair Value, Measurements, Recurring
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Total cash equivalents	0	0
Significant Other Observable Inputs (Level 2) | Commercial paper | Fair Value, Measurements, Recurring
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Total cash equivalents		16,602
Significant Other Observable Inputs (Level 2) | U.S. agency securities | Fair Value, Measurements, Recurring
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Total cash equivalents		3,970
Significant Unobservable Inputs (Level 3) | Fair Value, Measurements, Recurring
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Total cash equivalents		0
Total debt securities, available for sale		0
Total assets measured at fair value	0	0
Significant Unobservable Inputs (Level 3) | Commercial paper | Fair Value, Measurements, Recurring
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Total debt securities, available for sale		0
Significant Unobservable Inputs (Level 3) | U.S. agency securities | Fair Value, Measurements, Recurring
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Total debt securities, available for sale		0
Significant Unobservable Inputs (Level 3) | U.S. government securities | Fair Value, Measurements, Recurring
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Total debt securities, available for sale		0
Significant Unobservable Inputs (Level 3) | Money market funds | Fair Value, Measurements, Recurring
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Total cash equivalents	$ 0	0
Significant Unobservable Inputs (Level 3) | Commercial paper | Fair Value, Measurements, Recurring
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Total cash equivalents		0
Significant Unobservable Inputs (Level 3) | U.S. agency securities | Fair Value, Measurements, Recurring
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Total cash equivalents		$ 0

Fair Value of Financial Instr_4

Fair Value of Financial Instruments - Schedule of Financial Instruments Not Measured at Fair Value (Details) - Significant Other Observable Inputs (Level 2) - USD ($) $ in Thousands	Mar. 31, 2023	Dec. 31, 2022
Carrying Value
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Long-term debt, including current maturities	$ 68,886	$ 19,826
Fair Value
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Long-term debt, including current maturities	$ 70,000	$ 17,443

Property and Equipment, net - S

Property and Equipment, net - Schedule of Property and Equipment (Details) - USD ($) $ in Thousands	Mar. 31, 2023	Dec. 31, 2022
Property, Plant and Equipment [Line Items]
Total property and equipment	$ 72,093	$ 53,071
Less: Accumulated depreciation	(38,251)	(29,224)
Property and equipment, net	33,842	23,847
Assets held for sale	100	100
Equipment, tooling and molds
Property, Plant and Equipment [Line Items]
Total property and equipment	47,577	36,152
Computer software and equipment
Property, Plant and Equipment [Line Items]
Total property and equipment	8,037	2,667
Furniture, fixtures and other
Property, Plant and Equipment [Line Items]
Total property and equipment	2,600	2,007
Leasehold improvements
Property, Plant and Equipment [Line Items]
Total property and equipment	12,509	10,836
Construction in process
Property, Plant and Equipment [Line Items]
Total property and equipment	$ 1,370	$ 1,409

Property and Equipment, net - N

Property and Equipment, net - Narrative (Details) - USD ($) $ in Millions	3 Months Ended
	Mar. 31, 2023	Mar. 31, 2022	Dec. 31, 2022
Property, Plant and Equipment [Abstract]
Depreciation and amortization	$ 2.1	$ 1.9
Assets held for sale	$ 0.1		$ 0.1

Leases - Narrative (Details)

Leases - Narrative (Details) - USD ($) $ in Millions	3 Months Ended
	Mar. 31, 2023	Mar. 31, 2022
Leases [Abstract]
Sub-lease income	$ 0.1
Rent expense	0.9	$ 1.1
Variable lease payments	$ 0.8	$ 0.8

Leases - Maturity Schedule of O

Leases - Maturity Schedule of Operating Lease Liabilities (Details) - USD ($) $ in Thousands	Mar. 31, 2023	Dec. 31, 2022
Leases [Abstract]
Remainder of 2023	$ 4,691
2024	6,297
2025	5,952
2026	5,398
2027	4,759
Thereafter	7,464
Total undiscounted lease payments	34,561
Less: implied interest	(4,304)
Less: tenant improvement allowances receivable	(65)
Present value of operating lease payments	30,192
Less: current portion	(4,958)	$ (3,291)
Total long-term operating lease liabilities	$ 25,234	$ 22,726

Leases - Schedule of Supplement

Leases - Schedule of Supplemental Cash Flow Information Related to Operating Leases (Details) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2023	Mar. 31, 2022
Leases [Abstract]
Right-of-use assets obtained for new operating lease liabilities	$ 0	$ 0
Right-of-use lease assets assumed in IsoPlexis Merger	4,975	0
Cash paid for amounts included in the measurement of lease liabilities	$ 989	$ 1,098

Leases - Schedule of Additional

Leases - Schedule of Additional Information Related to Operating Leases (Details)	Mar. 31, 2023	Dec. 31, 2022
Leases [Abstract]
Weighted-average remaining lease term (in years)	5 years 8 months 15 days	6 years 5 months 23 days
Weighted-average discount rate	4.73%	4.66%

Long-Term Debt - Narrative (Det

Long-Term Debt - Narrative (Details) - USD ($)			3 Months Ended
	Mar. 21, 2023	Jun. 30, 2021	Mar. 31, 2023	Mar. 31, 2022	Mar. 20, 2023	Dec. 31, 2022	May 23, 2018
Debt Instrument [Line Items]
Loss on debt extinguishment			$ 162,000	$ 0
Restricted cash			70,093,000			$ 0
Interest cost			400,000	$ 200,000
EWB Term Loan
Debt Instrument [Line Items]
Restricted cash			70,000,000
Notes Payable
Debt Instrument [Line Items]
Loss on debt extinguishment			200,000
Commitment fee			$ 700,000
Notes Payable | EWB Term Loan
Debt Instrument [Line Items]
Maximum borrowing capacity	$ 70,000,000	$ 20,000,000			$ 20,000,000		$ 20,000,000
Note payable, term (in years)	60 months	48 months
Interest rate		4.17%
Interest-only period	24 months	24 months
Interest-only period with extension		36 months
Increase in borrowing capacity	$ 50,000,000
Prepayment penalty percentage	1%
Debt instrument, covenant description, cash	$ 70,000,000
Restricted cash	70,000,000
Debt instrument, covenant description, minimum cash and cash equivalents balance with bank	$ 100,000,000
Notes Payable | EWB Term Loan | Prime Rate
Debt Instrument [Line Items]
Interest rate	6.25%
Basis spread on variable rate	0.50%
Line of Credit | Perceptive Credit Agreement
Debt Instrument [Line Items]
Repayment of acquired debt	$ 52,500,000

Long-Term Debt - Schedule of Pa

Long-Term Debt - Schedule of Payment Due on Notes Payable (Details) - USD ($) $ in Thousands	Mar. 31, 2023	Dec. 31, 2022
Debt Instrument [Line Items]
Current portion, less loan discounts and financing costs	$ 0	$ (4,966)
Notes payable, net of current portion	68,886	$ 14,860
Notes Payable
Debt Instrument [Line Items]
Remainder of 2023	4,545
2024	6,049
2025	13,680
2026	15,437
2027	14,532
2028	41,990
Total payments due	96,233
Interest payments, loan discounts and financing costs	(27,347)
Current portion, less loan discounts and financing costs	0
Notes payable, net of current portion	$ 68,886

Equity and Stock Compensation_3

Equity and Stock Compensation Plans (Narrative) (Details) $ / shares in Units, $ in Millions		3 Months Ended
	Mar. 21, 2023 $ / shares shares	Mar. 31, 2023 USD ($) $ / shares	Dec. 31, 2022 $ / shares
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Purchase shares of common stock, par value (in dollars per share)		$ 0.00005	$ 0.00005
IsoPlexis Warrant
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Purchase shares of common stock, par value (in dollars per share)	$ 0.001
PhenomeX Warrant
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Conversion ratio	0.612
Purchase shares of common stock, par value (in dollars per share)	$ 0.00005
PhenomeX Warrant | Common Stock
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Warrant exercisable shares (in shares) | shares	496,560
Warrant exercise price per share (in dollars per share)	$ 9.80
IsoPlexis
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Conversion ratio	0.612
Exercise price per share (in dollars per share)	$ 1.28
Stock-based compensation | $		$ 0.1
IsoPlexis | Share-Based Payment Arrangement, Tranche One
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Award vesting rights, percentage	25%
Vesting period	1 year
IsoPlexis | Share-Based Payment Arrangement, Tranche Two
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Vesting period	36 months
IsoPlexis | RSAs
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Conversion ratio	0.612
Business acquisition, equity instruments other than options, number of shares acquired (in shares) | shares	304,619
IsoPlexis | Stock options
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Conversion ratio	0.612
Expiration period	10 years
Business acquisition, options, number of shares acquired (in shares) | shares	378,767

Equity and Stock Compensation_4

Equity and Stock Compensation Plans - Stock-Based Compensation (Details) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2023	Mar. 31, 2022
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]
Total stock-based compensation	$ 4,388	$ 5,393
Cost of sales
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]
Total stock-based compensation	16	51
Research and development
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]
Total stock-based compensation	548	1,581
Selling, general and administrative
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]
Total stock-based compensation	$ 3,824	$ 3,761

Restructuring - Narrative (Deta

Restructuring - Narrative (Details) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2023	Mar. 31, 2022
Restructuring and Related Activities [Abstract]
Restructuring charges	$ 1,290	$ 0
Total full-time employees (in percent)	16%

Restructuring - Changes in Rest

Restructuring - Changes in Restructuring Liability (Details) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2023	Mar. 31, 2022
Restructuring Reserve [Roll Forward]
Restructuring liability, beginning balance	$ 237
Restructuring liability assumed in IsoPlexis Merger	834
Restructuring charges	1,290	$ 0
Cash payments	(1,117)
Non-cash settlements	0
Restructuring liability, ending balance	1,244
Employee severance and termination benefits
Restructuring Reserve [Roll Forward]
Restructuring liability, beginning balance	130
Restructuring liability assumed in IsoPlexis Merger	834
Restructuring charges	1,290
Cash payments	(1,010)
Non-cash settlements	0
Restructuring liability, ending balance	1,244
Non labor restructuring
Restructuring Reserve [Roll Forward]
Restructuring liability, beginning balance	107
Restructuring liability assumed in IsoPlexis Merger	0
Restructuring charges	0
Cash payments	(107)
Non-cash settlements	0
Restructuring liability, ending balance	$ 0

Income Taxes (Details)

Income Taxes (Details) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2023	Mar. 31, 2022
Income Tax Disclosure [Abstract]
Provision for income taxes	$ 20	$ 20

Statements of Cash Flows (Detai

Statements of Cash Flows (Details) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2023	Mar. 31, 2022
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Cash paid for interest	$ 439	$ 137
Cash paid for income taxes	19	0
Non-cash investing and financing activities
Non-cash consideration for the acquisition of IsoPlexis	32,406	0
Property and equipment transferred to inventory	352	0
Customer return of Beacon transferred to property and equipment	201	0
Change in accounts payable and accrued liabilities related to purchases of property and equipment	$ 684	$ 482

Commitment and Contingencies -

Commitment and Contingencies - Narrative (Details)		1 Months Ended	3 Months Ended
	Jul. 01, 2021 claim patent	Dec. 31, 2021 investedCompany	Mar. 31, 2023 USD ($)
Loss Contingencies [Line Items]
Number of company invested | investedCompany		3
Loss contingency accrual			$ 0
Purchase obligations			$ 29,700,000
Product warranty, term			1 year
AbCellera and UBC
Loss Contingencies [Line Items]
Case management order, maximum number of patents allegedly infringed | patent	2
Case management order, maximum asserted patent claims per patent | claim	4

Commitment and Contingencies _2

Commitment and Contingencies - Product Warranty (Details) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2023	Mar. 31, 2022
Movement in Standard Product Warranty Accrual [Roll Forward]
Balance, beginning of period	$ 749	$ 1,085
Warranty accrual assumed in IsoPlexis Merger	128	0
Adjustments to existing warranties	(111)	(245)
Provision for new warranties	133	163
Settlement of pre-existing warranties	(111)	(89)
Balance, end of period	$ 788	$ 914

Net Loss Attributable to Comm_3

Net Loss Attributable to Common Stockholders Per Share - Schedule of Basic and Diluted Net Loss Per Share (Details) - USD ($) $ / shares in Units, $ in Thousands	3 Months Ended
	Mar. 31, 2023	Mar. 31, 2022
Numerator
Net loss attributable to common stockholders, basic	$ (23,419)	$ (21,426)
Net loss attributable to common stockholders, diluted	$ (23,419)	$ (21,426)
Denominator
Weighted-average shares used to compute net income per share, basic (in shares)	75,759,771	67,697,488
Weighted-average shares used to compute net income per share, diluted (in shares)	75,759,771	67,697,488
Net loss per share
Net loss per share attributable to common stockholders, basic (in dollars per share)	$ (0.31)	$ (0.32)
Net loss per share attributable to common stockholders, diluted (in dollars per share)	$ (0.31)	$ (0.32)

Net Loss Attributable to Comm_4

Net Loss Attributable to Common Stockholders Per Share - Schedule of Antidilutive Securities (Details) - shares	3 Months Ended
	Mar. 31, 2023	Mar. 31, 2022
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive securities excluded from the calculation of net loss per share (in shares)	13,990,891	10,649,901
Warrants to purchase common stock
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive securities excluded from the calculation of net loss per share (in shares)	496,560	0
Options to purchase common stock
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive securities excluded from the calculation of net loss per share (in shares)	7,685,997	7,020,591
Restricted stock awards
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive securities excluded from the calculation of net loss per share (in shares)	290,846	0
Restricted stock units
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive securities excluded from the calculation of net loss per share (in shares)	5,517,488	3,629,310

Segments (Details)

Segments (Details) $ in Thousands	3 Months Ended
	Mar. 31, 2023 USD ($) segment	Mar. 31, 2022 USD ($)
Revenues from External Customers and Long-Lived Assets [Line Items]
Number of operating segments | segment	1
Total revenue	$ 18,516	$ 20,206
North America
Revenues from External Customers and Long-Lived Assets [Line Items]
Total revenue	14,055	13,715
Asia Pacific
Revenues from External Customers and Long-Lived Assets [Line Items]
Total revenue	3,147	5,035
Europe
Revenues from External Customers and Long-Lived Assets [Line Items]
Total revenue	$ 1,314	$ 1,456

Subsequent Events (Details)

Subsequent Events (Details) - USD ($) $ in Millions	3 Months Ended
	Jun. 30, 2023	Mar. 31, 2023
Subsequent Event [Line Items]
Total full-time employees (in percent)		16%
Forecast
Subsequent Event [Line Items]
Total full-time employees (in percent)	12%
Severance and employee-related restructuring costs	$ 0.8